

OPI DATE 22/08/97 APPLN. ID 19581/97
 AOJP DATE 16/10/97 PCT NUMBER PCT/US97/01875



A09718581

D

(51) International Patent Classification ^b : A61K 31/095, 31/10		A1	(11) International Publication Number: WO 97/27847
			(43) International Publication Date: 7 August 1997 (07.08.97)
(21) International Application Number: PCT/US97/01875		(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).	
(22) International Filing Date: 31 January 1997 (31.01.97)			
(30) Priority Data: 60/011,025 2 February 1996 (02.02.96) US 9604232.0 28 February 1996 (28.02.96) GB		(81) Designated States: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		Published	
(72) Inventors; and (75) Inventors/Applicants (for US only): DOEBBER, Thomas, W. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). BERGER, Joel, P. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). BERGER, Gregory, D. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). LEIBOWITZ, Mark, D. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). MOLLER, David, E. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). OLSON, John, T. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). PATCHETT, Arthur, A. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US). TOUPENCE, Richard, B. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).		With international search report.	

(54) Title: METHOD OF TREATING DIABETES AND RELATED DISEASE STATES

(57) Abstract

The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.

- 1 -

TITLE OF THE INVENTION

METHOD OF TREATING DIABETES AND RELATED DISEASE STATES

This application is a continuation-in part and claims priority to U.S. provisional application: application no. 60/011025 filed February 2, 1996 (Merck attorney docket no. 19633PV) which is herein incorporated by reference in its entirety.

This application is related to the following U.S. non-provisional applications: Serial No. --/----- filed January 31, 1997 (Merck attorney docket no. 19869Y) which is herein incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

Diabetes refers to a disease process derived from multiple causative factors and characterized by elevated levels of plasma glucose or hyperglycemia. Uncontrolled hyperglycemia is associated with increased and premature mortality due to an increased risk for microvascular and macrovascular diseases, including nephropathy, neuropathy, retinopathy, hypertension, stroke, and heart disease. Therefore, control of glucose homeostasis is a critically important approach for the treatment of diabetes.

Type I diabetes (IDDM) is the result of an absolute deficiency of insulin, the hormone which regulates glucose utilization. Type II, noninsulin dependent diabetes mellitus (NIDDM) is due to a profound resistance to insulin stimulating or regulatory effect on glucose and lipid metabolism in the main insulin-sensitive tissues, muscle, liver and adipose tissue. This resistance to insulin responsiveness results in insufficient insulin activation of glucose uptake, oxidation and storage in muscle and inadequate insulin repression of lipolysis in adipose tissue and of glucose production and secretion in liver.

The several treatments for NIDDM, which has not changed substantially in many years, are all with limitations. While physical exercise and reductions in dietary intake of calories will dramatically

- 2 -

improve the diabetic condition, compliance with this treatment is very poor because of well-entrenched sedentary lifestyles and excess food consumption, especially high fat-containing food. Increasing the plasma level of insulin by administration of sulfonylureas (e.g. tolbutamide, glipizide) which stimulate the pancreatic β -cells to secrete more insulin or by injection of insulin after the response to sulfonylureas fails, will result in high enough insulin concentrations to stimulate the very insulin-resistant tissues. However, dangerously low levels of plasma glucose can result from these last two treatments and increasing insulin resistance due to the even higher plasma insulin levels could theoretically occur. The biguanides increase insulin sensitivity resulting in some correction of hyperglycemia. However, the two biguanides, phenformin and metformin, can induce lactic acidosis and nausea/diarrhea, respectively.

Thiazolidinediones (glitazones) are a recently disclosed class of compounds that are suggested to ameliorate many symptoms of NIDDM. These agents increase insulin sensitivity in muscle, liver and adipose tissue in several animal models of NIDDM resulting in complete correction of the elevated plasma levels of glucose, triglycerides and nonesterified free fatty acids without any occurrence of hypoglycemia. However, serious undesirable effects have occurred in animal and/or human studies including cardiac hypertrophy, hemadilution and liver toxicity resulting in few glitazones progressing to advanced human trials.

Hyperlipidemia is a condition which is characterized by an abnormal increase in serum lipids, such as cholesterol, triglycerides and phospholipids. These lipids do not circulate freely in solution in plasma, but are bound to proteins and transported as macromolecular complexes called lipoproteins. See the *Merck Manual*, 16th Ed. 1992 (see for example pp. 1039-1040) and "Structure and Metabolism of Plasma Lipoproteins" in *Metabolic Basis of Inherited Disease*, 6th Ed. 1989, pp. 1129-1138. One form of hyperlipidemia is hypercholesterolemia, characterized by the existence of elevated LDL cholesterol levels. The initial treatment for hypercholesterolemia is

- 3 -

often to modify the diet to one low in fat and cholesterol, coupled with appropriate physical exercise, followed by drug therapy when LDL-lowering goals are not met by diet and exercise alone. LDL is commonly known as the "bad" cholesterol, while HDL is the "good" cholesterol. Although it is desirable to lower elevated levels of LDL cholesterol, it is also desirable to increase levels of HDL cholesterol. Generally, it has been found that increased levels of HDL are associated with lower risk for coronary heart disease (CHD). See, for example, Gordon, et al., *Am. J. Med.*, 62, 707-714 (1977); Stampfer, et al., *N. England J. Med.*, 325, 373-381 (1991); and Kannel, et al., *Ann. Internal Med.*, 90, 85-91 (1979). An example of an HDL raising agent is nicotinic acid, but the quantities needed to achieve HDL raising are associated with undesirable effects, such as flushing.

It is suggested that thiazolidinedione compounds exert their effects by binding to the peroxisome proliferator activated receptor (PPAR) family of receptors, controlling certain transcription elements having to do with the biological entities listed above. See Hulin et al., *Current Pharm. Design* (1996) 2, 85-102. Three sub-types of PPARs have been discovered and described; they are PPAR α , PPAR γ and PPAR δ . PPAR α is activated by a number of medium and long-chain fatty acids, and it is involved in stimulating β -oxidation of fatty acids. PPAR α is also involved with the activity of fibrates in rodents and humans. Fibric acid derivatives such as clofibrate, fenofibrate, bezafibrate, ciprofibrate, beclofibrate and etofibrate, as well as gemfibrozil, produce a substantial reduction in plasma triglycerides along with moderate reduction in LDL cholesterol, and they are used particularly for the treatment of hypertriglyceridemia.

The PPAR γ receptor subtypes are involved in activating the program of adipocyte differentiation and are not involved in stimulating peroxisome proliferation in the liver. The DNA sequences for the PPAR γ receptors are described in Elbrecht, et al., *BBRC* 224:431-437 (1996). Although peroxisome proliferators, including the fibrates and fatty acids, activate the transcriptional activity of PPAR's, only prostaglandin J₂ derivatives have been identified as natural ligands of

- 4 -

the PPAR γ subtype, which also binds thiazolidinedione antidiabetic agents with high affinity. The glitazones have been shown to bind exclusively to the PPAR γ subtype.

The human nuclear receptor gene PPAR δ (hPPAR δ) has been cloned from a human osteosarcoma cell cDNA library and is fully described in A. Schmidt et al., *Molecular Endocrinology*, 6 :1634-1641 (1992), herein incorporated by reference. It should be noted that PPAR δ is also referred to in the literature as PPAR β and as NUC1, and each of these names refers to the same receptor; in Schmidt et al, the receptor is referred to as NUC1.


SUMMARY OF THE INVENTION

This invention is concerned with the compounds of formula I below and its analogs, pharmaceutically acceptable salts thereof, and bioprecursors thereof, which differ from the thiazolidinediones in that they lack the thiazolidinedione moiety and they do not lead to the array of toxicity's associated with the thiazolidinediones. The instant compounds are effective in treating diabetes, atherosclerosis, hyperglycemia, hyperlipidemia and/or obesity because they lower one or more of the following biological entities in mammals; glucose, insulin, triglycerides, fatty acids, cholesterol and the like. Thus, it is an object of this invention to describe such compounds. It is a further object to describe the specific preferred stereoisomers of the substituted compounds. A still further object is to describe processes for the preparation of such compounds. Another object is to describe methods and compositions which use the compounds as the active ingredient thereof. Further objects will become apparent from reading the following description.


DETAILED DESCRIPTION OF THE INVENTION

This invention is a method of using a compound of formula XI or XII:

- 5 -



and






or a pharmaceutically acceptable salt or acid addition salt thereof, or a pharmaceutically acceptable ester thereof, wherein:

each R is independently H, OH, alkyl of 1 to 6 carbon atoms which may be straight chain or branched; alkenyl of 2 to 6 carbon atoms which may be straight chain or branched; trifluoromethyl; alkoxy of 1 to 6 carbon atoms which may be straight chain or branched; SH; thioalkyl of 1 to 6 carbon atoms which may be straight chain or branched; phenyl; phenyl substituted by alkyl of 1 to 3 carbon atoms or by halogen; benzyl; phenethyl; halogen, amino; $\text{N}(\text{R}_4)_2$ wherein R_4 is H or alkyl of 1 to 6 carbon atoms which may be straight chain or branched; COOR_4 ; CH_2OR_4 ; formyl; CN; trifluoromethylthio; or nitro;

each R' is independently R_4 ; OR_4 ; COOR_4 ; $\text{N}(\text{R}_4)_2$; SR_4 ; CH_2OR_4 ; CHO; or together R' and R' are O; CH_2 ; or

- 6 -



Y' is sulfur, sulfoxide, sulfone;

R₁₁ is H, alkyl of 1-4 carbon atoms which may be straight chain or branched; alkanoyl of 1-4 carbon atoms which may be straight chain or branched; phenylsulfonyl; tosyl; NR₁₂ wherein R₁₂ is H, alkyl of 1-4 carbon atoms which may be straight chain or


branched; or $\text{N}-\overset{\text{O}}{\parallel}\text{C}-\text{R}_{13}$ wherein R₁₃ is alkyl of 1-4 carbon atoms which may be straight chain or branched, alkoxy of 1-4 carbon atoms which may be straight chain or branched; N-CN, CH₂, or C=O;

Y is Y' and oxygen;

each R₁ is independently hydrogen or alkyl of 1-3 carbon atoms;

each m is independently an integer from 0-6;

R₂ is



each R₆ is independently H or alkyl of 1-4 carbons;

P. 154 IUPAC

alkoxy

= R-O

alkyl dioxy

= O-R-O-


eg Phenoxyl



- 7 -


each R₇ is independently H, OH, or alkyl of 1-4 carbons;

each R₈ is independently H, or alkyl of 1-4 carbons, and is absent when a triple bond is present;



R₅ is COOR₄; CH₂OH; CHO; tetrazole; NHSO₂R₁₄;

hydroxymethylketone; CN; CON(R₇)₂; a monocyclic or bicyclic heterocyclic ring containing an acidic hydroxyl group; or COOR₁₅ where R₁₅ is




wherein each s is independently 0-3;


R₁₆ is

A) a monocyclic or bicyclic heterocyclic radical containing from 3 to 12 nuclear carbon atoms and 1 or 2 nuclear heteroatoms selected from N and S with at least one being N, and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or

B) the radical W-R₁₇ wherein W is O, S or NH and R₁₇ contains up to 21 carbon atoms and is (1) a hydrocarbon radical or (2) an acyl radical of an organic acyclic or monocyclic carboxylic acid containing not more than 1 heteroatom in the ring;



R₁₄ is OH, alkyl or alkoxy of 1 to 6 carbon atoms, phenyl or phenyl substituted by alkyl or alkoxy groups of 1 to 3 carbon atoms, halogen, hydroxy, haloalkyl, COOH, CN, formyl, acyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 4 carbon atoms;



- 8 -

r and q are each independently 0-20 provided that the total of r and q does not exceed 20;

p is 0 or 1;


R₃ is alkyl of 1 to 6 carbon atoms which may be straight chain or branched; or alkenyl of 3 to 6 carbon atoms which may be straight chain or branched as illustrated in formulas IV and V;

R₉ is alkyl of 1 to 6 carbon atoms which may be straight chain or branched; alkoxy of 1 to 6 carbon atoms which may be straight chain or branched; or $(\text{CH}_2)_r\text{R}_5$ and

R₁₀ is H; alkyl of 1 to 6 carbon atoms which may be straight chain or branched; $\text{R}_4\text{C}(=\text{O})-$ or R_4OCH_2- .

In one embodiment of the invention the compounds of formula XI and XII also include the following:

R₂ is



all other definitions remaining the same, except that when one of the R₇ groups is hydroxy, Y' may be oxygen.


As used herein, the terms "each independently" or the equivalents thereof are employed to described a number of possible position isomers and/or structural variations.

- 9 -

The invention is described herein in detail using the terms defined below unless otherwise specified.

The term "alkyl" refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 15 carbon atoms unless otherwise defined. It may be straight, branched or cyclic. Preferred straight or branched alkyl groups include methyl, ethyl, propyl, isopropyl, butyl and t-butyl. Preferred cycloalkyl groups include cyclopentyl and cyclohexyl.

Alkyl also includes a straight or branched alkyl group which contains or is interrupted by a cycloalkylene portion. Examples include the following:



wherein: x and y = from 0-10; and w and z = from 0-9.

The alkylene and monovalent alkyl portion(s) of the alkyl group can be attached at any available point of attachment to the cycloalkylene portion.

When substituted alkyl is present, this refers to a straight, branched or cyclic alkyl group as defined above, substituted with 1-3 groups as defined with respect to each variable.

The term "alkenyl" refers to a hydrocarbon radical straight, branched or cyclic containing from 2 to 15 carbon atoms and at least one carbon to carbon double bond. Preferably one carbon to carbon double bond is present, and up to four non-aromatic (non-resonating) carbon-carbon double bonds may be present. Preferred alkenyl groups include ethenyl, propenyl, butenyl and cyclohexenyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkenyl group may contain double bonds and may be substituted when a substituted alkenyl group is provided.

- 10 -

The term "alkynyl" refers to a hydrocarbon radical straight, branched or cyclic, containing from 2 to 15 carbon atoms and at least one carbon to carbon triple bond. Up to three carbon-carbon triple bonds may be present. Preferred alkynyl groups include ethynyl, propynyl and butynyl. As described above with respect to alkyl, the straight, branched or cyclic portion of the alkynyl group may contain triple bonds and may be substituted when a substituted alkynyl group is provided.






The term alkoxy represents an alkyl group of indicated carbon atoms attached through an oxygen linkage.

The term halo as used herein, represents fluoro, chloro, bromo or iodo.

The compounds of the present invention may be prepared by several different routes which are well published in the art. See EP 106565 B, incorporated by reference herein in its entirety.

According to one method a compound of formula I is reacted with an optionally alkyl substituted alkenyl halide of formula II wherein X is halogen and each R₆ is independently H or alkyl of 1-4 carbon atoms to yield the corresponding 2-hydroxy-4-alkenyloxy-acetophenone of formula III. The compound of formula III is then subjected to a Claisen rearrangement to yield a 2,4-dihydroxy-3-alkenyl-acetophenone compound of formula IV. This rearrangement occurs on heating the compound of formula III either neat or in a high boiling solvent, such as a halogenated hydrocarbon, e.g., dichlorobenzene, at from about 160 to about 210°C. The double bond in the compound of formula IV may then be reduced, e.g., by catalytic hydrogenation such as Pd/C, to yield the corresponding saturated compound of formula V.

- 11 -




The compound of formula V is then reacted with a dihaloalkane of formula VIa or a dihaloalkene of formula VIb wherein X, R and m have the meaning given previously, to yield a 4-(haloalkyloxy)-3-alkyl-2-hydroxyacetophenone compound of formula VII. The reaction takes place by refluxing a mixture of the compounds of formulas V and VIa or VIb in an inert solvent such as, for example, methylethylketone (MEK), acetone, tetrahydrofuran (THF), triglyme or dichloromethane in the presence of a base. The reflux temperature is preferably in the range of from about 60 to about 130°C. The base may be an alkali metal carbonate, for example, Li_2CO_3 , Na_2CO_3 or K_2CO_3 .


Specific examples of dihaloalkane compounds of formula VIa are 1,3-dibromopropane, 2-methyl-1,3-

- 12 -

dibromopropane, 2,2-dimethyl-1,3-dibromopropane, 3-chloro-2-chloromethyl-1-propene, 1,3-dibromobutane, 1,4-dibromobutane, 1,5-dibromopentane, 1,6-dibromo-hexane, 1,7-dibromoheptane, 1,8-dibromooctane, 1,9-di-bromononane, 1,10-dibromodecane, and 1,12-dibromo-dodecane. A specific example of a dihaloalkene compound of formula VIb is 1,4-dibromo-2-butene.




A compound of formula II is then react with a compound of formula V to yield a 4-alkenyloxy-3-alkyl-2-hydroxy-aceto-phenone compound of formula IX which is then epoxidized with an organic peracid such as, for example, m-chloroperbenzoic acid to give the compound of formula VIII.



The reaction of a compound of formula VIII with a compound of formula X under the same conditions used to react a compound of formula V with a compound of formula VIa or VIb gives a compound of formula XI or XII.

- 13 -



X

Additional compounds and the method for preparing them included within the scope of this invention are disclosed in US Patent Nos. 5,453,443, 4,820,867 and EP 0123541 and EP 0617001, all of which are incorporated by reference herein in their entirety.

A preferred compound of the instant method is 4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propylthio)-2,3-dichlorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy-propylthio)-2,3-dichlorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propylthio)-2,3-dichlorobenzeneacetic acid-S-oxide and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propylsulfonyl)-2,3-dichlorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-2,3-dichlorobenzeneacetic acid-S-oxide and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy-propylthio)-2,3-dichlorobenzeneacetic acid-S-oxide and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy-propylsulfonyl)-2,3-dichlorobenzeneacetic acid and its methyl ester;

- 14 -

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propylthio)-2-fluorobenzeneacetic acid and its methyl ester;

Sodium Salt of 4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-2-fluorobenzeneacetic acid, monohydrate and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-2-fluorobenzeneacetic acid-S-oxide and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylsulfonyl)-2-fluorobenzeneacetic acid; and 4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-1-propenylsulfonyl)-2-fluorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propylthio)-3-fluorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-3-fluorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propylthio)-3-chlorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propylthio)-3-chlorobenzeneacetic acid-S-oxide and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propyl-sulfonyl)-3-chlorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-3-chlorobenzeneacetic acid and its methyl ester;

- 15 -

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-3-chlorobenzeneacetic acid-S-oxide and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylsulfonyl)-3-chlorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propylthio)benzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propyl-sulfonyl)-benzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-methyl-propylthio)-benzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy-propylthio)-benzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy-propylthio)-3-fluorobenzoic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy-propylthio)-3-fluorobenzoic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylsulfonyl)-3-fluorobenzoic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propylthio)-3-fluorobenzoic acid-S-oxide, methyl ester and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propyl-sulfonyl)-3-fluorobenzoic acid and its methyl ester; and

- 16 -

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propyl-cyanamido)-benzeneacetic acid and its methyl ester.

Compounds of the general Formula XI or XII may be separated into diastereoisomeric pairs of enantiomers by, for example, fractional crystallization from a suitable solvent, for example methanol or ethyl acetate or a mixture thereof. The pair of enantiomers thus obtained may be separated into individual stereoisomers by conventional means, for example by the use of an optically active acid as a resolving agent.

Alternatively, any enantiomer of a compound of the general Formula I may be obtained by stereospecific synthesis using optically pure starting materials of known configuration.

The instant compounds can be isolated in the form of their pharmaceutically acceptable acid addition salts, such as the salts derived from using inorganic and organic acids. Examples of such acids are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, malonic and the like. In addition, certain compounds containing an acidic function such as a carboxy or tetrazole, can be isolated in the form of their inorganic salt in which the counterion can be selected from sodium, potassium, lithium, calcium, magnesium and the like, as well as from organic bases.

As previously indicated, the compounds of the present invention have valuable pharmacological properties. They are useful in treating or preventing diabetes, treating obesity, lowering triglyceride levels and prevention of vascular restenosis. They are useful in treating other disorders where insulin resistance is a component including ovarian hyperandrogenism (polycystic ovarian syndrome). They are also useful in raising high density lipoprotein levels, preventing, halting or slowing the progression of atherosclerotic cardiovascular diseases and related conditions and disease events.

The present invention also provides a compound of the general Formula I or a pharmaceutically acceptable salt thereof for use as an active therapeutic substance.

- 17 -

The present invention further provides a compound of the general Formula I, or a pharmaceutically acceptable ester thereof; or pharmaceutically acceptable salt thereof, for use in the treatment of hyperglycemia (diabetes) in human or non-human animals.

The present invention further provides a compound of the general Formula I, or a pharmaceutically acceptable ester thereof; or pharmaceutically acceptable salt thereof, in combination with known sulfonylureas, other insulin secretagogues as well as insulin for use in the treatment of diabetes treating obesity, lowering triglyceride levels, prevention of vascular restenosis, treating other disorders where insulin resistance is a component including ovarian hyperandrogenism (polycystic ovarian syndrome), raising high density lipoprotein levels, and preventing, halting or slowing the progression of atherosclerotic cardiovascular diseases and related conditions and disease events and hypertension in human or non-human animals.

In one aspect, the present invention provides a compound of the general Formula I for use in the treatment of obesity in human or non-human animals. Said compound can be effectively used in combination with other known or proposed strategies for the treatment of obesity or obesity-related disorders; for example, fenfluramine, dexfenfluramine, phentiramine and β_3 adrenergic receptor agonist agents.

The disease diabetes mellitus is characterized by metabolic defects in production and utilization of glucose which result in the failure to maintain appropriate blood sugar levels. The result of these defects is elevated blood glucose or hyperglycemia. Research on the treatment of diabetes has centered on attempts to normalize fasting and postprandial blood glucose levels. Treatments have included parenteral administration of exogenous insulin, oral administration of drugs and dietary therapies. The instant compounds can be effectively used in combination with known therapies for diabetes including insulin, sulfonylureas, biguanides (such as metformin), α -glucosidase inhibitors (such as acarbose) and others.

- 18 -

Two major forms of diabetes mellitus are now recognized. Type I diabetes, or insulin-dependent diabetes, is the result of an absolute deficiency of insulin, the hormone which regulates glucose utilization. Type II diabetes, or non-insulin-independent diabetes, often occurs in the face of normal, or even elevated levels of insulin and appears to be the result of the inability of tissues to respond appropriately to insulin. Most of the Type II diabetics are also obese. Accordingly, in another aspect the present invention provides a method of lowering triglyceride levels which comprises administering, to an animal in need thereof, a therapeutically effective amount of a compound of the formula I or pharmaceutically acceptable salt or ester thereof.

In addition the compounds of the present invention lower or modulate triglyceride levels and/or cholesterol levels and raise HDL plasma levels and are therefore of use in combating medical conditions wherein such lowering (and raising) is thought to be beneficial. Thus they may be used in the treatment of hypertension, obesity, atherosclerotic disease events, diabetes and related conditions by administering to an animal in need thereof, a therapeutically effective amount of a compound of the formula (I) or pharmaceutically acceptable salt thereof. The compositions are formulated and administered in the same general manner as detailed below. They may also contain other active ingredients known for use in the treatment of atherosclerotic disease events, diabetes, hypertension, obesity and related conditions, for example fibrates such as clofibrate, bezafibrate and gemfibrozil; inhibitors of cholesterol biosynthesis such as HMG-CoA reductase inhibitors for example lovastatin, simvastatin and pravastatin; inhibitors of cholesterol absorption for example beta-sitosterol and (acyl CoA:cholesterol acyltransferase) inhibitors for example melinamide; anion exchange resins for example cholestyramine, colestipol or a dialkylaminoalkyl derivatives of a cross-linked dextran; nicotiny alcohol, nicotinic acid or a salt thereof; vitamin E; and thyromimetics.

- 19 -

In particular the invention provides methods for preventing or reducing the risk of developing atherosclerosis, comprising the administration of a prophylactically effective amount of a compound of formula I alone or in combination with one or more additional pharmaceutically active agents, to a mammal, particularly human, who is at risk of developing atherosclerosis.

Atherosclerosis encompasses vascular diseases and conditions that are recognized and understood by physicians practicing in the relevant fields of medicine. Atherosclerotic cardiovascular disease, coronary heart disease (also known as coronary artery disease or ischemic heart disease), cerebrovascular disease and peripheral vessel disease are all clinical manifestations of atherosclerosis and are therefore encompassed by the terms "atherosclerosis" and "atherosclerotic disease."

The instant invention further provides methods for preventing or reducing the risk of a first or subsequent (where the potential exists for recurrence) atherosclerotic disease event, comprising the administration of a prophylactically effective amount, or more particularly an effective amount of a cholesterol biosynthesis inhibitor, of a compound of formula I alone or in combination with one or more additional pharmaceutically active agents, to a mammal, particularly human, who is at risk for having an atherosclerotic disease event. The term "atherosclerotic disease event" as used herein is intended to encompass coronary heart disease events, cerebrovascular events, and intermittent claudication. Coronary heart disease events are intended to include CHD death, myocardial infarction (i.e., a heart attack), and coronary revascularization procedures. Cerebrovascular events are intended to include ischemic or hemorrhagic stroke (also known as cerebrovascular accidents) and transient ischemic attacks. Intermittent claudication is a clinical manifestation of peripheral vessel disease. It is intended that persons who have previously experienced one or more non-fatal atherosclerotic disease event are those for whom the potential for recurrence of such an event exists.

- 20 -

Persons to be treated with the instant therapy include those at risk of developing atherosclerotic disease and of having an atherosclerotic disease event. Standard atherosclerotic disease risk factors are known to the average physician practicing in the relevant fields of medicine. Such known risk factors include but are not limited to hypertension, smoking, diabetes, low levels of high density lipoprotein cholesterol, high levels of low density lipoprotein cholesterol, and a family history of atherosclerotic cardiovascular disease. Published guidelines for determining those who are at risk of developing atherosclerotic disease can be found in: National Cholesterol Education Program, Second report of the Expert Panel on *Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)*, National Institute of Health, National Heart Lung and Blood Institute, NIH Publication No. 93-3095, September 1993; *abbreviated version*: Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, *Summary of the second report of the national cholesterol education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)*, *JAMA*, 1993, 269, pp. 3015-23. People identified as having one or more of the above-noted risk factors, as well as people who already have atherosclerosis, are intended to be included within the group of people considered to be at risk for having an atherosclerotic disease event.

The active compounds of the present invention may be orally administered as a pharmaceutical composition, for example, with an inert diluent, or with an assimilable edible carrier, or they may be enclosed in hard or soft shell capsules, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet. For oral therapeutic administration, which includes sublingual administration, these active compounds may be incorporated with excipients and used in the form of tablets, pills, capsules, ampules, sachets, elixirs, suspensions, syrups, and the like. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of

- 21 -

course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that an effective dosage will be obtained. The active compounds can also be administered intranasally as, for example, liquid drops or spray.

The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated.

When treating or preventing diabetes mellitus and/or hyperglycemia or hypertriglyceridemia, or obesity, or when treating, preventing or slowing the progression of atherosclerosis generally satisfactory results are obtained when the compounds of the present invention are administered at a daily dosage of from about 0.1 milligram to about 100 milligram per kilogram of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or in sustained release form. For most large mammals, the total daily dosage is from about 1.0 milligrams to about 1000 milligrams, preferably from about 1 milligrams to about 50 milligrams. In the case of a 70 kg adult human, the total daily dose will generally be from about 7 milligrams to about 350 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response.

The compositions are formulated and administered in the same general manner as detailed below. The compounds of the instant invention may be used effectively alone or in combination with one or more additional active agents depending on the desired target therapy. Combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound of formula I and one or more additional active agents, as well as administration of a compound of formula I and each active agent in its own separate pharmaceutical dosage formulation. For example, a compound of formula I and an HMG-CoA reductase inhibitor can be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent

- 22 -

administered in separate oral dosage formulations. Where separate dosage formulations are used, a compound of formula I and one or more additional active agents can be administered at essentially the same time, i.e., concurrently, or at separately staggered times, i.e., sequentially; combination therapy is understood to include all these regimens.

An example of combination treatment or prevention of atherosclerosis may be wherein a compound of formula I is administered in combination with one or more of the following active agents: *an anti:hyperlipidemic agent; a plasma HDL-raising agent; an antihypercholesterolemic agent such as a cholesterol biosynthesis inhibitor, for example an HMG-CoA reductase inhibitor, an HMG-CoA synthase inhibitor, a squalene epoxidase inhibitor, or a squalene synthetase inhibitor (also known as squalene synthase inhibitor); an acyl-coenzyme A: cholesterol acyltransferase (ACAT) inhibitor such as melinamide; probucol; nicotinic acid and the salts thereof and niacinamide; a cholesterol absorption inhibitor such as beta-sitosterol; a bile acid sequestrant anion exchange resin such as cholestyramine, colestipol or dialkylaminoalkyl derivatives of a cross-linked dextran; an LDL (low density lipoprotein) receptor inducer; fibrates such as clofibrate, bezafibrate, fenofibrate, and gemfibrozil; vitamin B6 (also known as pyridoxine) and the pharmaceutically acceptable salts thereof such as the HCl salt; vitamin B12 (also known as cyanocobalamin); anti-oxidant vitamins such as vitamin C and E and beta carotene; a beta-blocker; an angiotensin II antagonist; an angiotensin converting enzyme inhibitor; and a platelet aggregation inhibitor such as fibrinogen receptor antagonists (i.e., glycoprotein IIb/IIIa fibrinogen receptor antagonists) and aspirin.* As noted above, the compounds of formula I can be administered in combination with more than one additional active agent, for example, a combination of a compound of formula I with an HMG-CoA reductase inhibitor (e.g. lovastatin, simvastatin and pravastatin) and aspirin, or a compound of formula I with an HMG-CoA reductase inhibitor and a beta blocker.

- 23 -

Another example of combination therapy can be seen in treating obesity or obesity-related disorders, wherein the compounds of formula I may be effectively used in combination with for example, fenfluramine, dexfenfluramine, phentiramine and β_3 adrenergic receptor agonist agents.

Still another example of combination therapy can be seen in treating diabetes and related disorders wherein the compounds of formula I can be effectively used in combination with for example sulfonylureas, biguanides, α -glucosidase inhibitors, other insulin secretagogues, insulin as well as the active agents discussed above for treating atherosclerosis.

In accordance with this invention, a pharmaceutically effective amount of a compound of formula I can be used for the preparation of a medicament useful for treating diabetes, treating obesity, lowering tryglyceride levels, raising the plasma level of high density lipoprotein, and for treating, preventing or reducing the risk of developing atherosclerosis, and for preventing or reducing the risk of having a first or subsequent atherosclerotic disease event in mammals, particularly in humans.

Additionally, an effective amount of a compound of formula I and a therapeutically effective amount of one or more active agents selected from the group consisting of: *an antihyperlipidemic agent; a plasma HDL-raising agent; an antihypercholesterolemic agent such as a cholesterol biosynthesis inhibitor, for example an HMG-CoA reductase inhibitor, an HMG-CoA synthase inhibitor, a squalene epoxidase inhibitor, or a squalene synthetase inhibitor (also known as squalene synthase inhibitor); an acyl-coenzyme A: cholesterol acyltransferase inhibitor; probucol; nicotinic acid and the salts thereof; niacinamide; a cholesterol absorption inhibitor; a bile acid sequestrant anion exchange resin; a low density lipoprotein receptor inducer; clofibrate, fenofibrate, and gemfibrozol; vitamin B6 and the pharmaceutically acceptable salts thereof; vitamin B12; an anti-oxidant vitamin; a beta-blocker; an angiotensin II antagonist; an angiotensin converting enzyme inhibitor; a platelet aggregation inhibitor; a*

- 24 -

fibrinogen receptor antagonist; aspirin; fenfluramines, dexfenfluramines, phentiramines, β_3 adrenergic receptor agonists; sulfonylureas, biguanides, α -glucosidase inhibitors, other insulin secretagogues, and insulin can be used together for the preparation of a medicament useful for the above-described treatments.

The tablets, pills, capsules, and the like may also contain a binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin. When a dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil.

Various other materials may be present as coatings or to modify the physical form of the dosage unit. For instance, tablets may be coated with shellac, sugar or both. A syrup or elixir may contain, in addition to the active ingredient, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and a flavoring such as cherry or orange flavor.

These active compounds may also be administered parenterally. Solutions or suspensions of these active compounds can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and

- 25 -

liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

Specific examples of formula I may require the use of protecting groups to enable their successful elaboration into the desired structure. Protecting groups may be chosen with reference to Greene, T.W., et al., Protective Groups in Organic Synthesis, John Wiley & Sons, Inc., 1991. The blocking groups are readily removable, i.e., they can be removed, if desired, by procedures which will not cause cleavage or other disruption of the remaining portions of the molecule. Such procedures include chemical and enzymatic hydrolysis, treatment with chemical reducing or oxidizing agents under mild conditions, treatment with fluoride ion, treatment with a transition metal catalyst and a nucleophile, and catalytic hydrogenation.

Examples of suitable hydroxyl protecting groups are: trimethylsilyl, triethylsilyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, t-butyldiphenylsilyl, t-butyldimethylsilyl, benzyloxycarbonyl, t-butyloxycarbonyl, 2,2,2-trichloroethyloxycarbonyl, and allyloxycarbonyl. Examples of suitable carboxyl protecting groups are benzhydryl, o-nitrobenzyl, p-nitrobenzyl, 2-naphthylmethyl, allyl, 2-chloroallyl, benzyl, 2,2,2-trichloroethyl, trimethylsilyl, t-butyldimethylsilyl, t-butldiphenylsilyl, 2-(trimethylsilyl)ethyl, phenacyl, p-methoxybenzyl, acetonyl, p-methoxyphenyl, 4-pyridylmethyl and t-butyl.

The compounds used in the method of the invention can be prepared readily according in the following detailed examples using readily available starting materials, reagents and conventional synthesis procedures. In these reactions, it is also possible to make use of variants which are themselves known to those of ordinary skill in this art, but which are not mentioned in greater detail. Additional background information and further details on the preparation of the compounds of formula XI and XII is taught in EP B-106565, the entire disclosure of which is incorporated herein by reference.

EXAMPLE 1

- 27 -

Step C: Preparation of 2,3-dichloro-4-hydroxy-benzeneacetic acid, methyl ester.

2,3-Dichloro-4-methoxybenzeneacetic acid, methyl ester, 46 gm, was refluxed for 18 hours in concentrated HBr, 350 mL. The reaction mixture was poured in water, 1.4 L, and the solution was extracted with EtOAc, 2 x 500 mL. The organic layers were washed with water, dried (Na_2SO_4) and concentrated to dryness. The residue was slurried in 20% EtOAc-hexane to yield 2,3-dichloro-4-hydroxybenzeneacetic acid, mp 189-190°C. The acid was stirred at room temperature in methanolic HCl, 100 mL, for 30 minutes. The volatiles were removed in vacuo and the residue was slurried in hexane, filtered and air-dried to yield 17.6 gm of the title compound, mp 105-106°C, analysis, calculated: C, 45.98; H, 3.43; Cl, 30.16; obtained: C, 46.10; H, 3.65; Cl, 30.31.

Step D: Preparation of 2,3-dichloro-4-dimethyl-thiocarbamoyloxybenzeneacetic acid, methyl ester

Sodium hydride, 99%, 1.3 gm, was added to a solution of 2,3-dichloro-4-hydroxybenzeneacetic acid, methyl ester, 11.4 gm, in DMF, 100 mL. The mixture was stirred until evolution of H_2 gas subsided. Dimethylthiocarbamoyl chloride, 6.5 gm, was then added and the reaction mixture was stirred at room temperature for 18 hours. The reaction mixture was poured in water, 200 mL, and was extracted with ether, 500 mL. The ether layer was washed with water, dried (Na_2SO_4) and concentrated in vacuo to yield an oil that was purified by chromatography on silica gel to yield 11.7 gm of the title compound, mp 87-93°C, analysis, calculated: C, 44.73; H, 4.06; N, 4.34; S, 9.95; Cl, 22.00; obtained: C, 44.44; H, 4.15; N, 4.05; S, 9.05; Cl, 21.65.

Step E: Preparation of 2,3-dichloro-4-dimethyl-carbamoylthiobenzeneacetic acid, methyl ester
2,3-Dichloro-4-dimethylthiocarbamoylbenzene-

- 28 -

acetic acid, methyl ester, 10.7 gm, was heated under N₂ atmosphere at 250°C for 30 minutes. The reaction mixture was cooled to room temperature and after a purification by chromatography on silica gel, the title compound, 6.8 gm, was obtained, mp 119-122°C, analysis, calculated: C, 44.73; H, 4.06; N, 4.34; S, 9.95; Cl, 22.00; obtained: C, 44.50; H, 4.21; N, 4.25; S, 10.19; Cl, 22.57.

Step F: Preparation of the sodium salt of 2,3-dichloro-4-mercaptobenzeneacetic acid, methyl ester
2,3-Dichloro-4-dimethylcarbamoylthiobenzeneacetic acid, methyl ester, 3.22 gm, was refluxed in methanol, 60 mL, containing sodium methoxide, 855 mg, for 1 hour. The reaction mixture, containing about 10 millimoles of the sodium salt of the title compound, in 60 mL MeOH, was used as such in Step G.

Step G: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylthio)-2,3-dichlorobenzeneacetic acid, methyl ester
To 30 mL of the solution obtained in Step F was added 4-(3-bromopropoxy)-3-propyl-2-hydroxyacetophenone, 1.73 gm, and the reaction mixture was refluxed for 2 hours. It was then poured in water and extracted with EtOAc. The extract was washed with water, dried (Na₂SO₄) and concentrated in vacuo. The title compound, mp 82-85°C was obtained by chromatography of the residue on silica gel.

Step H: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylthio)-2,3-dichlorobenzeneacetic acid
The ester prepared in Step F, 964 mg, dissolved in 1N NaOH, 10 mL, and in methanol, 30 mL, was refluxed for 30 minutes. The volatiles were evaporated in vacuo. The residue was taken up in water and the resulting solution was acidified with 20% citric acid. The mixture was extracted with EtOAc, the extracts

- 29 -

were washed with water, dried (Na_2SO_4) and concentrated in vacuo to yield the title compound, mp 119-122°C.

EXAMPLE 2

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-2,3-dichlorobenzeneacetic acid

Step A: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-2,3-dichlorobenzeneacetic acid, methyl ester

By following Step G of Example 1, but substituting 4-(2,3-epoxypropoxy)-3-propyl-2-hydroxy- acetophenone for 4-(3-bromopropoxy)-3-propyl-2-hydroxyacetophenone, the title compound, mp 85-88°C, was obtained.

Step B: 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-2,3-dichlorobenzeneacetic acid

By following Step H of Example 1, but substituting the product of Step A of this example for the ester of Step G of Example 1, the title compound, mp 151-153°C, was obtained.

EXAMPLE 3

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propylthio)-2,3-dichlorobenzeneacetic acid-S-oxide

Step A: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylthio)-2,3-dichlorobenzene-acetic acid-S-oxide, methyl ester

The product obtained in Step G of Example 1, 1.4 gm, in CH_2Cl_2 , 35 mL, was treated with m-chloroperbenzoic acid, 560 mg, for 15 minutes at 0°C. $\text{Ca}(\text{OH})_2$, 3 gm, was added and the resulting suspension was stirred for 10 minutes. The solids were filtered off and the filtrate was concentrated in vacuo to yield the title compound, mp 153-155°C.

- 30 -

Step B: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylthio)-2,3-dichlorobenzene-acetic acid-S-oxide

By following Step H of Example 1, but substituting the product of Step A of this example for the ester of Step G of Example 1, the title compound, mp 162-164°C, was obtained.

EXAMPLE 4

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propylsulfonyl)-2,3-dichlorobenzeneacetic acid

Step A: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylsulfonyl)-2,3-dichlorobenzeneacetic acid, methyl ester

The product obtained in Step G of Example 1, 1.4 gm, in CH₂Cl₂, 35 mL, was treated with m-chloroperbenzoic acid, 1.15 gm, for 2 hours at room temperature. Ca(OH)₂, 4 gm, was added and the resulting suspension was stirred for 10 minutes. The solids were filtered off and the filtrate was concentrated in vacuo to yield the title compound, mp 115-118°C.

Step B: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylsulfonyl)-2,3-dichlorobenzeneacetic acid

By following Step H of Example 1, but substituting the product of Step A of this example for the ester of Step G of Example 1, the title compound, mp 180-181°C, was obtained.

EXAMPLE 5

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-2,3-dichlorobenzeneacetic acid-S-oxide

Step A: Preparation of 4-(3-(4-acetyl-3-hydroxy-

- 31 -

2-propylphenoxy)-2-hydroxypropylthio)-2,3-dichlorobenzeneacetic acid-S-oxide, methyl ester

By following Step A of Example 3, but substituting the product of Step A of Example 2 for the ester of Step G of Example 1, the title compound, mp 149-152°C, was obtained.

Step B: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-2,3-dichlorobenzeneacetic acid-S-oxide

By following Step H of Example 1 but substituting the product of Step A of this example for the ester of Step G of Example 1, the title compound, mp 166-170°C, was obtained.

EXAMPLE 6

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylsulfonyl)-2,3-dichlorobenzeneacetic acid

Step A: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylsulfonyl)-2,3-dichlorobenzeneacetic acid, methyl ester

By following Step A of Example 4, but substituting the product of Step A of Example 2 for the ester from Step G of Example 1, the title compound, mp 122-125°C, was obtained.

Step B: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylsulfonyl)-2,3-dichlorobenzeneacetic acid

By following Step H of Example 1, but substituting the product from Step A of this example for the ester of Step G of Example 1, the title compound, mp 181-183°C, was obtained.

EXAMPLE 7

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propylthio)-2-fluorobenzeneacetic acid

- 32 -

Step A: Preparation of 4-methoxy-2-fluoroacetophenone
By following Step A of Example 1, but substituting m-fluoroanisole for 2,3-dichloroanisole, the title compound, mp 50-52°C, was obtained.

Step B: Preparation of 4-methoxy-2-fluorobenzene-acetic acid, methyl ester
By following Step B of Example 1 but substituting 4-methoxy-2-fluoroacetophenone for 2,3-dichloro-4-methoxyacetophenone, the title compound, bp 112-115°C/1 Torr, was obtained.

Step C: Preparation of 4-hydroxy-2-fluorobenzene acetic acid, methyl ester
By following Step C of Example 1 but substituting 4-methoxy-2-fluorobenzeneacetic acid, methyl ester for 2,3-dichloro-4-methoxybenzeneacetic acid, methyl ester, 4-hydroxy-2-fluorobenzeneacetic acid was obtained as a sticky solid which was treated with methanolic HCl to yield the title compound as an oil. It was characterized by its NMR spectrum: (ppm) (CDCl₃) 3.70 (3H, s, CH₃O), 3.55 (2H, s, CH₂).

Step D: Preparation of 2-fluoro-4-dimethylthiocarbamoyloxybenzeneacetic acid, methyl ester
By following Step D of Example 1 but substituting 4-hydroxy-2-fluorobenzeneacetic acid, methyl ester for 4-hydroxy-2,3-dichlorobenzeneacetic acid, methyl ester, the title compound, mp 113-114°C, was obtained.

Step E: Preparation of 2-fluoro-4-dimethylthiocarbamoylthiobenzeneacetic acid, methyl ester
By following Step E of Example 1 but substituting 2-fluoro-4-dimethylthiocarbamoyloxybenzeneacetic acid, methyl ester

- 33 -

for 2,3-dichloro-4-dimethylthiocarbamoyloxybenzeneacetic acid, methyl ester, the title compound, mp 79-81°C, was obtained.

Step F: Preparation of the sodium salt of 2-fluoro-4-mercaptobenzeneacetic acid, methyl ester

By following Step F of Example 1 but substituting 2-fluoro-4-dimethylcarbamoylthiobenzene-acetic acid, methyl ester for 2,3-dichloro-4-dimethyl-carbamoylthiobenzeneacetic acid, methyl ester a solution of the title compound was obtained and was used as such in the following Step.

Step G: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylthio-2-fluorobenzene-acetic acid, methyl ester

By following Step G of Example 1 but substituting the product of Step F of this example for the product of Step F of Example 1, the title compound, mp 63-65°C, was obtained.

Step H: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)propylthio-2-fluorobenzene-acetic acid

By following Step H of Example 1, but substituting the methyl ester of Step G of this example for the methyl ester of Step G of Example 1, the title compound, mp 154-156°C, was obtained.

EXAMPLE 8

Sodium Salt of 4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio-2-fluorobenzeneacetic acid, monohydrate

Step A: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio-2-fluorobenzeneacetic acid, methyl ester

By following Step G of Example 7, but substituting 4-(2,3-epoxypropoxy)-3-propyl-2-hydroxy-acetophenone for 4-(3-

- 34 -

bromopropoxy)-3-propyl-2-hydroxyacetophenone, the title compound was obtained as an oil. Analysis, calculated: C, 61.31; H, 6.04; F, 4.21; S, 7.11; obtained: C, 61.08; H, 6.51; F, 3.93; S, 6.69.

Step B: Preparation of the sodium salt of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-2-fluorobenzeneacetic acid, monohydrate

By following Step H of Example 7, but substituting the product of Step A of this example for the ester of Step G of Example 7, the corresponding acid of the title compound was obtained as an oil. It was treated with one equivalent of sodium hydroxide in water to yield, after evaporation of the water, the title compound, mp 75-83°C, analysis, calculated: C, 55.45; H, 5.50; F, 3.98; S, 6.73; obtained: C, 55.55; H, 5.56; F, 4.71; S, 6.99.

EXAMPLE 9

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-2-fluorobenzeneacetic acid-S-oxide

Step A: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-2-fluorobenzeneacetic acid-S-oxide, methyl ester

By following Step A of Example 3, but substituting the title compound of Step A of Example 8 for the title compound of Step G of Example 1, the title compound is obtained.

Step B: Preparation 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-2-fluorobenzeneacetic acid-S-oxide

By following Step H of Example 2, but substituting the product of Step A of this example for the ester of Step G of Example 1, the title compound is obtained.

- 35 -

EXAMPLE 10

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylsulfonyl)-2-fluorobenzeneacetic acid; and
4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-1-propenylsulfonyl)-2-fluorobenzeneacetic acid

Step A: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylsulfonyl)-2-fluorobenzeneacetic acid, methyl ester

By following Step A of Example 4, but substituting the product of Step A of Example 8 for the title compound of Step G of Example 1, the title compound, mp 118-119°C, was obtained.

Step B: Preparation of 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylsulfonyl)-2-fluorobenzeneacetic acid; and
4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-propenylsulfonyl)-2-fluorobenzeneacetic acid

By following Step H of Example 1, but substituting the product of Step A of this example for the ester of Step G of Example 1, a mixture was obtained. After recrystallization from diethyl ether, 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylsulfonyl)-2-fluorobenzeneacetic acid, mp 119-120°C, was obtained. The mother liquors were purified by chromatography on silica gel to yield 4-(3-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-propenyl-sulfonyl)-2-fluoro-benzene acetic acid, mp 249-251°C.

BIOLOGICAL ASSAYS

The ability of compounds of the present invention to enhance the insulin activation of ¹⁴C-glucose incorporation into glycogen in white adipose tissue (WAT) was determined by the following assay.

BIOLOGICAL ASSAYS

1. White Adipose Tissue *in vitro* Assay

The ability of compounds of the present invention to enhance the insulin activation of ^{14}C -glucose incorporation into glycogen in white adipose tissue (WAT) was determined by the following assay.

This assay measures the efficacy of the instant compounds to enhance the insulin activation of ^{14}C -glucose incorporation into glycogen in white adipose tissue (WAT) in a 5 hour completely *in vitro* system. All procedures are performed in medium 199 containing 1% bovine serum albumen, 5 mM HEPES, and antibiotic (100 units/ml penicillin, 100 $\mu\text{g}/\text{ml}$ streptomycin sulfate, 0.25 $\mu\text{g}/\text{ml}$ amphotericin B), hereafter called culture medium. Epididymol fat pads are minced with scissors into small fragments, approximately 1 mm in diameter. Minced WAT fragments (100 mg) are incubated in a total volume of 0.9 ml culture medium containing 1 mU/ml insulin and test compound in tissue culture incubator at 37°C with 5% CO_2 with orbital shaking for 3 hours. ^{14}C -labeled glucose is added and incubation continued for 2 hours. Tubes are centrifuged at low speed, infranatant is removed and 1 M NaOH is added. Incubation of alkali-treated WAT for 10 minutes at 60°C solubilizes tissue. Resulting tissue hydrolyzate is applied to Whatman filter paper strips which are then rinsed in 66% ethanol followed by 100% acetone which removes unincorporated ^{14}C -glucose from bound ^{14}C -glycogen. The dried paper is then incubated in solution of amyloglucosidase to cleave glycogen into glucose. Scintillation fluid is added and samples are counted for ^{14}C activity. Test compounds that resulted in ^{14}C activity substantially above incubations with insulin alone are considered active insulin-enhancing agents. Active compounds were titrated to determine the compound concentration which resulted in 50% of maximum enhancement of insulin activation and were termed EC_{50} values. EC_{50} values for the instant compounds were found to be 50 μM or less, preferably 5.0 to .0001 μM or less.

- 38 -

- (b) removing unbound ligand by adding dextran/gelatin-coated charcoal to each sample while maintaining the samples at 4 °C and allowing at least 10 minutes to pass, then
- (c) subjecting each of the test samples and the control sample from step (b) to centrifugation at 4 °C until the charcoal is pelleted; then
- (d) counting a portion of the supernatant fraction of each of the test samples and the control sample from step (c) in a liquid scintillation counter and analyzing the results to determine the IC₅₀ of the test compound.

In the hPPAR δ binding assay, preferably at least four test samples of varying concentrations of a single test compound are prepared in order to determine the IC₅₀.

The hPPAR δ transactivation assay comprises the steps of:


- (a) seeding an hPPAR δ /GR stable CHO-K1 cell line into alpha MEM containing 10% FCS, 10 mM HEPES, and 500 mg/ml G418 at 37°C in an atmosphere of 10% CO₂ in air,
- (b) incubating the cells from step (a) for 16 to 48 hours, preferably about 20 hours, at 37°C in an atmosphere of 10% CO₂ in air;
- (c) washing the cells from step (b) with alpha MEM;
- (d) preparing multiple test cell groups by incubating separate groups of the cells from step (c) with the test compound in alpha MEM containing 5% charcoal stripped FCS, 10 mM HEPES, and 500 mg/ml G418, for 24 to 48 hours, preferably about 24 hours, at 37°C in an atmosphere of 10% CO₂ in air, wherein the concentration of the test compound in each test cell group is different, and preparing a control cell group by incubating a further separate group of the cells from step (c) under the same conditions but without the test compound; then
- (e) preparing cell lysates from each of the test cell groups and the control cell group of step (d) using an aqueous detergent lysis buffer, and
- (f) measuring the luciferase activity of the test cell groups and the control cell group of step (e) and analyzing the results to determine the EC₅₀ of the test compound.

- 39 -

In the hPPAR δ transactivation assay, preferably at least four test cell groups of varying concentrations of a single test compound are prepared in order to determine the EC₅₀.

Particular terms and abbreviations used herein are defined as follows: gst is glutathione-S-transferase; EDTA is ethylenediamine-tetraacetic acid; HEPES is N-[2-hydroxyethyl]-piperazine-N'-[2-ethanesulfonic acid]; FCS is fetal calf serum; Lipofectamine is a 3:1 (w/w) liposome formulation of the polycationic lipid 2,3-dioleoyloxy-N-[2(spermine-carboxamido)ethyl]-N,N-dimethyl-1-propanaminium-trifluoroacetate and the neutral lipid dioleoyl phosphatidylethanolamine in water; G418 is geneticin; MEM is Minimum Essential Medium; Opti MEM 1 Reduced-Serum Medium is an aqueous composition containing HEPES buffer, 2400 mg/L sodium bicarbonate, hypoxanthine, thymidine, sodium pyruvate, L-glutamine, trace elements, growth factors, and phenol red reduced to 1.1 mg/L; Luciferase Assay Reagent (in re-constituted form) is an aqueous composition containing 20 mM tricine, 1.07 mM (MgCO₃)₄Mg(OH)₂·5H₂O, 2.67 mM MgSO₄, 0.1 mM EDTA, 33.3 mM DTT, 270 μ M coenzyme A, 470 μ M luciferin, 530 μ M ATP, having a final pH of 7.8.

AD-5075 has the following structure:



AD-5075 (Takeda)

Opti MEM 1 Reduced-Serum Medium, alpha MEM, G418, and Lipofectamine are commercially available from GibcoBRL Life Technologies, Gaithersburg, Maryland. Alpha MEM is an aqueous composition having the following components:

- 40 -

Component: Inorganic Salts	mg/L
CaCl ₂ (anhyd.)	200.00
CaCl ₂ •2H ₂ O	--
KCl	400.00
MgSO ₄ (anhyd.)	97.67
MgSO ₄ •7H ₂ O	--
NaCl	6800.00
NaHCO ₃	2200.00
NaH ₂ PO ₄ •H ₂ O	140.00
NaH ₂ PO ₄ •2H ₂ O	--
Other Components:	mg/L
D-Glucose	1000.00
Lipoic Acid	0.20
Phenol Red	10.00
Sodium Pyruvate	110.00
Amino Acids:	mg/L
L-Alanine	25.00
L-Arginine•HCl	126.00
L-Asparagine•H ₂ O	50.00
L-Aspartic Acid	30.00
L-Cystine	--
L-Cystine•2HCl	31.00
L-Cysteine HCl	--
L-Cysteine HCl•H ₂ O	100.00
L-Glutamic Acid	75.00
L-Glutamine	292.00

- 41 -

L-Alanyl-L-Glutamine	--
Glycine	50.00
L-Histidine HCl•H ₂ O	42.00
L-Isoleucine	52.00
L-Leucine	52.00
L-Lysine•HCl	73.00
L-Methionine	15.00
L-Phenylalanine	32.00
L-Proline	40.00
L-Serine	25.00
L-Threonine	48.00
L-Tryptophan	10.00
L-Tyrosine	--
L-Tyrosine (disodium salt)	52.00
L-Valine	46.00
Vitamins:	mg/L
L-Ascorbic acid	50.00
Biotin	0.10
D-Ca Pantothenate	1.00
Choline Chloride	1.00
Folic acid	1.00
i-Inositol	2.00
Niacinamide	1.00
Pyridoxal HCl	1.00
Riboflavin	0.10
Thiamine HCl	1.00

- 42 -

Vitamin B ₁₂	1.40
Ribonucleosides	mg/L
Adenosine	10.00
Cytidine	10.00
Guanosine	10.00
Uridine	10.00
Deoxyribonucleosides	mg/L
2' Deoxyadenosine	10.00
2' Deoxycytidine HCl	11.00
2' Deoxyguanosine	10.00
Thymidine	10.00

The instant compounds, which are useful for treating the above discussed disease states, will preferably have IC₅₀ values at one, two or all of the PPAR (PPAR γ , PPAR δ or PPAR α) receptor cites of equal to or less than 10 μ M binding assay, and an EC₅₀ equal to or less than 10 μ M in the transactivation assay. Preferably, an IC₅₀ of 100 nM in the binding assay, and an EC₅₀ equal to or less than 100 nM in the transactivation assay. More preferably, the instant compounds have an IC₅₀ equal to or less than 50 nM in the binding assay, and an EC₅₀ equal to or less than 50 nM in the transactivation assay. Most preferably, the instant compounds have an IC₅₀ equal to or less than 10 nM in the binding assay, and an EC₅₀ equal to or less than 10 nM in the transactivation assay..

PPAR Receptor Binding Assay

A. Preparation of Human PPAR γ 2 and δ

Human PPAR γ 2 and PPAR δ , independently, were prepared as gst-fusion proteins in *E. coli*. The full length human cDNA for PPAR γ 2 and PPAR δ were subcloned into the PGEX-2T and PGEX-KT,

- 43 -

respectively, expression vector (Pharmacia). *E. coli* containing the plasmid were grown, induced, and then harvested by centrifugation. The resuspended pellet was broken in a French press and debris was removed by centrifugation at 12,000Xg. Receptors were purified from the supernatant by affinity chromatography on glutathione sepharose. After application to the column, and 1 wash, receptor was eluted with glutathione. Glycerol was added to stabilize the receptor and aliquots were frozen at -80 °C for later use.

B. [³H]AD-5075 and Example 11 Displacement Assay for PPAR γ 2 and PPAR δ , respectively

For each assay, an aliquot of receptor (1:1000-1:3000 dilution) was incubated in TEGM (10 mM Tris, pH 7.2, 1 mM EDTA, 10% glycerol, 7 μ l/100 ml β -mercaptoethanol, 10 mM Na molybdate, 1 mM dithiothreitol, 5 μ g/ml aprotinin, 2 μ g/ml leupeptin, 2 μ g/ml benzamide and 0.5 mM PMSF) containing 5-10% COS-1 cell cytoplasmic lysate and 10 nM labeled thiazolidinedione ([³H₂]AD-5075, 21 Ci/mmol), \pm test compound compound, [³H₂]Example 11, 17 Ci/mmol), \pm test compound, respectively. Assays were incubated for ~16 h at 4 °C in a final volume of 300 μ l. Unbound ligand was removed by addition of 200 μ l dextran/gelatin-coated charcoal, on ice, for ~10 minutes. After centrifugation at 3000 rpm for 10 min at 4 °C, 200 μ l of the supernatant fraction was counted in a liquid scintillation counter. In this assay the K_D for AD-5075 and Example 11 is 1 nM, respectively.

PPAR Receptor Transactivation Assay

A. Activation of hPPAR γ and hPPAR δ Methods

1. Plasmids

The chimeric receptor expression constructs, pSG5-hPPAR γ 2/GR and pSG5-hPPAR δ /GR, were prepared by inserting the DNA binding domain of the murine glucocorticoid receptor adjacent to the ligand binding domain of hPPAR γ 2 or hPPAR δ . These vectors were kindly provided by Dr. Azriel Schmidt (MRL). The glucocorticoid receptor -responsive reporter vector, pMMTV/luc/neo, contains the

- 44 -

murine mammary tumour virus (MMTV) promoter adjacent to the luciferase gene (luc) and the neomycin resistance gene (neo). It was constructed from pMMTV/luc which was provided by Dr. Azriel Schmidt (Merck Research Laboratories). Prior to transfection into CHO-K1 cells, pSG5-hPPAR γ 2/GR and pSG5-hPPAR δ /GR were linearized with Xba I. pMMTV/luc/neo DNA was cut with Pvu I. Wild type receptor constructs, pSG5-hPPAR γ 2, pSG5-hPPAR δ and pSG5-hPPAR α were prepared by inserting the full-length hPPAR γ 2, hPPAR δ and PPAR α cDNAs adjacent to the SV40 promoter in pSG5. The PPAR-responsive reporter construct, pPPRE-luc, contained 3 copies of a generic PPRE placed adjacent to the thymidine kinase minimal promoter and the luciferase reporter gene. The transfection control vector, pCMV-lacZ, contains the galactosidase Z gene under the regulation of the cytomegalovirus promoter.

2. Production of stable cell lines

CHO-K1 cells were seeded overnight at 6×10^5 cells /60 mm dish in alpha Minimum Essential Medium (MEM) containing 10% fetal calf serum (FCS), 10 mM HEPES, 100 units/ml PenicillinG and 100 μ g/ml Streptomycin sulfate at 37°C in an atmosphere of 10% CO₂ in air. The cells were washed once with OptiMEM 1 Reduced-Serum Medium and then cotransfected with 4.5 μ g of pSG5-hPPAR γ 2 /GR or pSG5-hPPAR δ /GR expression vector and 0.5 μ g of pMMTV/luc/neo in the presence of 100 μ g Lipofectamine (GIBCO BRL) according to the instructions of the manufacturer. Transfection medium was removed 2 h later and replaced with growth medium. After being incubated for 3 days, cells were subcultured by diluting the cell suspension 1/1250 and 1/6250 and placing the cells in a 100 mm culture dish. Selection of the stable cell lines was initiated the next day by adding 500 μ g/ml G418 to the medium. Cells were routinely fed with the selection media for 1 month at which time 120 colonies were picked and transferred to 24 well culture plates. Ten days later, confluent colonies were transferred to 6 well plates to maintain stocks and to 96 well plates to assay for luciferase activity. Positive clones were characterized and validated by

- 45 -

titrating 4 known agonists on each clone. Two clones, g2B2P2D9 and d2A5P2G3, were selected for screening purposes.

B. hPPAR/GR transactivation screens in stably transfected CHO-K1 cells

The hPPAR γ 2/GR and hPPAR δ /GR stable CHO-K1 cell lines were seeded at 1×10^4 cells/well in 96 well cell culture plates in alpha MEM containing 10% FCS, 10 mM HEPES, and 500 mg/ml G418 at 37°C in an atmosphere of 10% CO₂ in air. After a 20 hour incubation, cells were washed once with alpha MEM and then incubated in an atmosphere of 10% CO₂ in air in alpha MEM containing 5% charcoal stripped FCS, 10 mM HEPES, and 500 mg/ml G418. The cells were incubated for 24 hours in the absence of test compound or in the presence of a range of concentrations of test compound. Cell lysates were prepared from washed cells using Reporter Lysis Buffer (Promega) according to the manufacturer's directions. Luciferase activity in cell extracts was determined using Luciferase Assay Reagent buffer (Promega) in a ML3000 luminometer (Dynatech Laboratories).

Transactivation Wild-Type Assay

A. Characterization of ligand activity on wild-type hPPAR γ , hPPAR δ and hPPAR α .

COS-1 cells were seeded at 0.5×10^5 cells/dish into 24 well plates in Dulbecco's modified Eagle medium (high glucose) containing 10% charcoal stripped fetal calf serum, nonessential amino acids, 100 units/ml Penicillin G and 100 μ g/ml Streptomycin sulfate at 37°C in a humidified atmosphere of 10% CO₂. After 24 hours, transfections were performed with Lipofectamine (Gibco-BRL, Gaithersburg, MD) according to the instructions of the manufacturer. In general, for transactivation experiments, transfection mixes contained 0.15 mg of hPPAR γ 2 hPPAR α or hPPAR δ expression vector, 0.15 mg of reporter vector pPPRE-luc and 0.001 mg of pCMV-lacZ as an internal control of transfection efficiency. Compounds demonstrating

- 46 -

significant agonist activity in the above primary screen were further characterized by incubation with transfected cells for 48h across a range of concentrations. Luciferase activity was determined as described above.

In a similar manner, hPPAR γ 1 cDNA can be used in place of hPPAR γ 2 cDNA in the methods described in Example 5 to make the wild type receptor construct, pSG5-hPPAR γ 1.

III. In Vivo Studies

Methods

db/db Mice are obese, highly insulin resistant animals. The db locus has been shown to code for the leptin receptor. These animals are substantially hypertriglyceridemic and hyperglycemic.

Male db/db mice (10-11 week old C57Bl/KFJ, Jackson Labs, Bar Harbor, ME) were housed 5/cage and allowed *ad lib.* access to ground Purina rodent chow and water. The animals, and their food, were weighed every 2 days and were dosed daily by gavage with vehicle (0.5% carboxymethylcellulose) \pm test compound at the indicated dose. Drug suspensions were prepared daily. Plasma glucose, Cholesterol and triglyceride concentrations were determined from blood obtained by tail bleeds at 3-5 day intervals during the study period. Glucose, cholesterol and triglyceride, determinations were performed on a Boehringer Mannheim Hitachi 911 automatic analyzer (Boehringer Mannheim, Indianapolis, IN) using heparinized plasma diluted 1:5, or 1:6 (v/v) with normal saline. Lean animals were age-matched heterozygous mice maintained in the same manner. The instant compounds were found to lower triglyceride and glucose levels at a dose of about 100mg/kg, preferably a dose of about 10-50 mg/kg, when administered by oral gavage daily for a period of at least 5 days.

Lipoprotein analysis was performed on either serum, or EDTA treated plasma obtained by heart puncture from anesthetized animals at the end of the study. Apolipoprotein concentrations were determined by ELISA, and cholesterol particles were analyzed by FPLC, precipitation, or ultracentrifugation. Total liver RNA was


- 47 -

prepared from tissue that had been frozen on liquid nitrogen at the time of euthanasia. Apolipoprotein mRNA was analyzed on Northern Blots using specific probes for mouse or rat proteins.


- 48 -

WHAT IS CLAIMED IS:

1. A method for the treatment or prevention of diabetes which comprises administering to a diabetic patient a pharmaceutically effective amount of a compound of formula XI or XII:



and




or a pharmaceutically acceptable salt or acid addition salt thereof, wherein:

each R is independently H, OH, alkyl of 1 to 6 carbon atoms which may be straight chain or branched; alkenyl of 2 to 6 carbon atoms which may be straight chain or branched; trifluoromethyl; alkoxy of 1 to 6 carbon atoms which may be straight chain or branched; SH; thioalkyl of 1 to 6 carbon atoms which may be straight chain or branched; phenyl; phenyl substituted by alkyl of 1 to 3 carbon atoms or by halogen; benzyl; phenethyl; halogen, amino; N(R₄)₂ wherein R₄ is H or alkyl of 1 to 6 carbon atoms which may be straight chain or branched; COOR₄; CH₂OR₄; formyl; CN; trifluoromethylthio; or nitro;

- 49 -

each R' is independently R₄; OR₄; COOR₄; N(R₄)₂;
 SR₄; CH₂OR₄; CHO; or together R' and R' are O; CH₂; or



Y' is sulfur, sulfoxide, sulfone; $\text{S}=\text{NR}_{11}$;

R₁₁ is H, alkyl of 1-4 carbon atoms which may be straight chain or branched; alkanoyl of 1-4 carbon atoms which may be straight chain or branched; phenylsulfonyl; tosyl; NR₁₂ wherein R₁₂ is H, alkyl of 1-4


carbon atoms which may be straight chain or branched; or $\text{N}-\overset{\text{O}}{\parallel}{\text{C}}-\text{R}_{13}$ wherein R₁₃ is alkyl of 1-4 carbon atoms which may be straight chain or branched, alkoxy of 1-4 carbon atoms which may be straight chain or branched; N-CN, CH₂, or C=O;

Y is Y' and oxygen;

each R₁ is independently hydrogen or alkyl of 1-3 carbon atoms;

each m is independently an integer from 0-6;

R₂ is




each R₆ is independently H or alkyl of 1-4 carbons;

- 50 -

each R₇ is independently H, OH, or alkyl of 1-4 carbons;

each R₈ is independently H, or alkyl of 1-4 carbons, and is absent when a triple bond is present;

R₅ is COOR₄; CH₂OH; CHO; tetrazole; NHSO₂R₁₄; hydroxymethylketone; CN; CON(R₇)₂; a monocyclic or bicyclic heterocyclic ring containing an acidic hydroxyl group; or COOR₁₅ where R₁₅ is



wherein each s is independently 0-3;

R₁₆ is

- A) a monocyclic or bicyclic heterocyclic radical containing from 3 to 12 nuclear carbon atoms and 1 or 2 nuclear heteroatoms selected from N and S with at least one being N, and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or
- B) the radical W-R₁₇ wherein W is O, S or NH and R₁₇ contains up to 21 carbon atoms and is (1) a hydrocarbon radical or (2) an acyl radical of an organic acyclic or monocyclic carboxylic acid containing not more than 1 heteroatom in the ring;

R₁₄ is OH, alkyl or alkoxy of 1 to 6 carbon atoms, phenyl or phenyl substituted by alkyl or alkoxy groups of 1 to 3 carbon atoms, halogen, hydroxy, haloalkyl, COOH, CN, formyl, acyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 4 carbon atoms;

r and q are each independently 0-20 provided that the total of r and q does not exceed 20;

- 51 -

p is 0 or 1;

R₃ is alkyl of 1 to 6 carbon atoms which may be straight chain or branched; or alkenyl of 3 to 6 carbon atoms which may be straight chain or branched as illustrated in formulas IV and V;

R₉ is alkyl of 1 to 6 carbon atoms which may be straight chain or branched; alkoxy of 1 to 6 carbon atoms which may be straight chain or branched; or (CH₂)_rR₅; and

R₁₀ is H; alkyl of 1 to 6 carbon atoms which may be straight chain or

branched; $\text{R}_4\overset{\text{O}}{\parallel}\text{C}-$ or R₄OCH₂-.

2. A method according to Claim 1 wherein the compound is Y is oxygen and Y' is sulfur, sulfoxide, sulfone, amino or cyanamido.

3. A method according to Claim 1 wherein each m is 1.


4. A method according to Claim 1 wherein the compound is

(A) 4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propylthio)-2,3-dichlorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy-propylthio)-2,3-dichlorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propylthio)-2,3-dichlorobenzeneacetic acid-S-oxide and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propylsulfonyl)-2,3-dichlorobenzeneacetic acid and its methyl ester;



- 52 -

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-2,3-dichlorobenzeneacetic acid-S-oxide and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy-propylthio)-2,3-dichlorobenzeneacetic acid-S-oxide and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy-propylsulfonyl)-2,3-dichlorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propylthio)-2-fluorobenzeneacetic acid and its methyl ester;

Sodium Salt of 4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-2-fluorobenzeneacetic acid, monohydrate and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy-propylthio)-2-fluorobenzeneacetic acid-S-oxide and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylsulfonyl)-2-fluorobenzeneacetic acid; and 4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-1-propenylsulfonyl)-2-fluorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)propylthio)-3-fluorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-3-fluorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propylthio)-3-chlorobenzeneacetic acid and its methyl ester;

- 53 -

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propylthio)-3-chlorobenzeneacetic acid-S-oxide and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propyl-sulfonyl)-3-chlorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-3-chlorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylthio)-3-chlorobenzeneacetic acid-S-oxide and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylsulfonyl)-3-chlorobenzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propyl-thio)benzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propyl-sulfonyl)-benzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-methyl-propylthio)-benzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy-propylthio)-benzeneacetic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy-propylthio)-3-fluorobenzoic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy-propylthio)-3-fluorobenzoic acid and its methyl ester;

- 54 -

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxypropylsulfonyl)-3-fluorobenzoic acid and its methyl ester;

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propylthio)-3-fluorobenzoic acid-S-oxide, methyl ester and its methyl ester;


4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propyl-sulfonyl)-3-fluorobenzoic acid and its methyl ester; and

4-(3-(4-Acetyl-3-hydroxy-2-propylphenoxy)-propyl-cyanamido)-benzeneacetic acid and its methyl ester.


5. A method for the treatment or prevention of diabetes which comprises administering to a diabetic patient an effective amount of a compound of Claim 1 in combination with a sulfonylurea, fibrate, HMG-CoA reductase inhibitor, beta-sitosterol inhibitor, cholesterol acyltransferase inhibitor, biguanides, cholestyramine, angiotensin II antagonist, melinamide, nicotinic acid, fibrinogen receptor antagonists, aspirin, α -glucosidase inhibitors, insulin secretagogue or insulin.

6. A method for treating obesity which comprises administering to a patient in need thereof an effective amount of a compound of formula XI or XII:

- 55 -



and




or a pharmaceutically acceptable salt or acid addition salt thereof,
wherein:

each R is independently H, OH, alkyl of 1 to 6 carbon atoms which may be straight chain or branched; alkenyl of 2 to 6 carbon atoms which may be straight chain or branched; trifluoromethyl; alkoxy of 1 to 6 carbon atoms which may be straight chain or branched; SH; thioalkyl of 1 to 6 carbon atoms which may be straight chain or branched; phenyl; phenyl substituted by alkyl of 1 to 3 carbon atoms or by halogen; benzyl; phenethyl; halogen, amino; $N(R_4)_2$ wherein R_4 is H or alkyl of 1 to 6 carbon atoms which may be straight chain or branched; $COOR_4$; CH_2OR_4 ; formyl; CN; trifluoromethylthio; or nitro;

each R' is independently R_4 ; OR_4 ; $COOR_4$; $N(R_4)_2$;
 SR_4 ; CH_2OR_4 ; CHO; or together R' and R' are O; CH_2 ; or

- 56 -



Y' is sulfur, sulfoxide, sulfone; $\text{S}=\text{NR}_{11}$;

R_{11} is H, alkyl of 1-4 carbon atoms which may be straight chain or branched; alkanoyl of 1-4 carbon atoms which may be straight chain or branched; phenylsulfonyl; tosyl; NR_{12} wherein R_{12} is H, alkyl of 1-4


carbon atoms which may be straight chain or branched; or $\text{N}-\overset{\text{O}}{\parallel}{\text{C}}-\text{R}_{13}$ wherein R_{13} is alkyl of 1-4 carbon atoms which may be straight chain or branched, alkoxy of 1-4 carbon atoms which may be straight chain or branched; N-CN, CH_2 , or $\text{C}=\text{O}$;

Y is Y' and oxygen;

each R_1 is independently hydrogen or alkyl of 1-3 carbon atoms;

each m is independently an integer from 0-6;

R_2 is




each R_6 is independently H or alkyl of 1-4 carbons;

each R_7 is independently H, OH, or alkyl of 1-4 carbons;

- 57 -

each R₈ is independently H, or alkyl of 1-4 carbons, and is absent when a triple bond is present;

R₅ is COOR₄; CH₂OH; CHO; tetrazole; NHSO₂R₁₄; hydroxymethylketone; CN; CON(R₇)₂; a monocyclic or bicyclic heterocyclic ring containing an acidic hydroxyl group; or COOR₁₅ where R₁₅ is



wherein each s is independently 0-3;

R₁₆ is

- A) a monocyclic or bicyclic heterocyclic radical containing from 3 to 12 nuclear carbon atoms and 1 or 2 nuclear heteroatoms selected from N and S with at least one being N, and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or
- B) the radical W-R₁₇ wherein W is O, S or NH and R₁₇ contains up to 21 carbon atoms and is (1) a hydrocarbon radical or (2) an acyl radical of an organic acyclic or monocyclic carboxylic acid containing not more than 1 heteroatom in the ring;

R₁₄ is OH, alkyl or alkoxy of 1 to 6 carbon atoms, phenyl or phenyl substituted by alkyl or alkoxy groups of 1 to 3 carbon atoms, halogen, hydroxy, haloalkyl, COOH, CN, formyl, acyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 4 carbon atoms;

r and q are each independently 0-20 provided that the total of r and q does not exceed 20;

p is 0 or 1;

- 58 -

R₃ is alkyl of 1 to 6 carbon atoms which may be straight chain or branched; or alkenyl of 3 to 6 carbon atoms which may be straight chain or branched as illustrated in formulas IV and V;

R₉ is alkyl of 1 to 6 carbon atoms which may be straight chain or branched; alkoxy of 1 to 6 carbon atoms which may be straight chain or branched; or (CH₂)_rR₅; and


R₁₀ is H; alkyl of 1 to 6 carbon atoms which may be straight chain or

branched; $\text{R}_4\overset{\text{O}}{\underset{\parallel}{\text{C}}}-$ or R₄OCH₂-.


7. A method according to Claim 6 in combination with a fenfluramine, dexfenfluramine, phentiramine or β_3 adrenergic receptor agonist.

8. A method for lowering triglyceride levels which comprises administering to a patient needing lower triglyceride an effective amount of a compound of formula XI or XII:

- 59 -



and




or a pharmaceutically acceptable salt or acid addition salt thereof,
wherein:

each R is independently H, OH, alkyl of 1 to 6 carbon atoms which may be straight chain or branched; alkenyl of 2 to 6 carbon atoms which may be straight chain or branched; trifluoromethyl; alkoxy of 1 to 6 carbon atoms which may be straight chain or branched; SH; thioalkyl of 1 to 6 carbon atoms which may be straight chain or branched; phenyl; phenyl substituted by alkyl of 1 to 3 carbon atoms or by halogen; benzyl; phenethyl; halogen, amino; $N(R_4)_2$ wherein R_4 is H or alkyl of 1 to 6 carbon atoms which may be straight chain or branched; $COOR_4$; CH_2OR_4 ; formyl; CN; trifluoromethylthio; or nitro;

each R' is independently R_4 ; OR_4 ; $COOR_4$; $N(R_4)_2$; SR_4 ; CH_2OR_4 ; CHO; or together R' and R'' are O; CH_2 ; or

- 60 -



Y' is sulfur, sulfoxide, sulfone; $\text{S}=\text{NR}_{11}$;

R₁₁ is H, alkyl of 1-4 carbon atoms which may be straight chain or branched; alkanoyl of 1-4 carbon atoms which may be straight chain or branched; phenylsulfonyl; tosyl; NR₁₂ wherein R₁₂ is H, alkyl of 1-4


carbon atoms which may be straight chain or branched; or $\text{N}-\overset{\text{O}}{\parallel}{\text{C}}-\text{R}_{13}$ wherein R₁₃ is alkyl of 1-4 carbon atoms which may be straight chain or branched, alkoxy of 1-4 carbon atoms which may be straight chain or branched; N-CN, CH₂, or C=O;

Y is Y' and oxygen;

each R₁ is independently hydrogen or alkyl of 1-3 carbon atoms;

each m is independently an integer from 0-6;

R₂ is




each R₆ is independently H or alkyl of 1-4 carbons;

each R₇ is independently H, OH, or alkyl of 1-4 carbons;

- 61 -

each R_8 is independently H, or alkyl of 1-4 carbons, and is absent when a triple bond is present;

R_5 is COOR_4 ; CH_2OH ; CHO ; tetrazole; $\text{NHSO}_2\text{R}_{14}$; hydroxymethylketone; CN ; $\text{CON}(\text{R}_7)_2$; a monocyclic or bicyclic heterocyclic ring containing an acidic hydroxyl group; or COOR_{15} where R_{15} is



wherein each s is independently 0-3;

R_{16} is

- A) a monocyclic or bicyclic heterocyclic radical containing from 3 to 12 nuclear carbon atoms and 1 or 2 nuclear heteroatoms selected from N and S with at least one being N, and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or
- B) the radical W-R_{17} wherein W is O, S or NH and R_{17} contains up to 21 carbon atoms and is (1) a hydrocarbon radical or (2) an acyl radical of an organic acyclic or monocyclic carboxylic acid containing not more than 1 heteroatom in the ring;

R_{14} is OH, alkyl or alkoxy of 1 to 6 carbon atoms, phenyl or phenyl substituted by alkyl or alkoxy groups of 1 to 3 carbon atoms, halogen, hydroxy, haloalkyl, COOH , CN , formyl, acyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 4 carbon atoms;

r and q are each independently 0-20 provided that the total of r and q does not exceed 20;

p is 0 or 1;


- 62 -

R_3 is alkyl of 1 to 6 carbon atoms which may be straight chain or branched; or alkenyl of 3 to 6 carbon atoms which may be straight chain or branched as illustrated in formulas IV and V;


R_9 is alkyl of 1 to 6 carbon atoms which may be straight chain or branched; alkoxy of 1 to 6 carbon atoms which may be straight chain or branched; or $(CH_2)_7R_5$; and

R_{10} is H; alkyl of 1 to 6 carbon atoms which may be straight chain or branched; $R_4C(=O)-$ or R_4OCH_2- .

9. A method for halting, preventing or reducing the risk of developing atherosclerosis and related disease events in a patient in need of such treatment, comprising the administration of a pharmaceutically effective amount of a compound of formula XI or XII:



and




- 63 -

or a pharmaceutically acceptable salt or acid addition salt thereof, wherein:

each R is independently H, OH, alkyl of 1 to 6 carbon atoms which may be straight chain or branched; alkenyl of 2 to 6 carbon atoms which may be straight chain or branched; trifluoromethyl; alkoxy of 1 to 6 carbon atoms which may be straight chain or branched; SH; thioalkyl of 1 to 6 carbon atoms which may be straight chain or branched; phenyl; phenyl substituted by alkyl of 1 to 3 carbon atoms or by halogen; benzyl; phenethyl; halogen, amino; $N(R_4)_2$ wherein R_4 is H or alkyl of 1 to 6 carbon atoms which may be straight chain or branched; $COOR_4$; CH_2OR_4 ; formyl; CN; trifluoromethylthio; or nitro;

each R' is independently R_4 ; OR_4 ; $COOR_4$; $N(R_4)_2$; SR_4 ; CH_2OR_4 ; CHO; or together R' and R' are O; CH_2 ; or



Y' is sulfur, sulfoxide, sulfone; $\begin{array}{c} \text{O} \\ \parallel \\ \text{S}=\text{NR}_{11} \end{array}$;

R_{11} is H, alkyl of 1-4 carbon atoms which may be straight chain or branched; alkanoyl of 1-4 carbon atoms which may be straight chain or branched; phenylsulfonyl; tosyl; NR_{12} wherein R_{12} is H, alkyl of 1-4

carbon atoms which may be straight chain or branched; or $\begin{array}{c} \text{O} \\ \parallel \\ \text{N}-\text{C}-\text{R}_{13} \end{array}$ wherein R_{13} is alkyl of 1-4 carbon atoms which may be straight chain or branched, alkoxy of 1-4 carbon atoms which may be straight chain or branched; N-CN, CH_2 , or C=O;


- 64 -

Y is Y' and oxygen;

each R₁ is independently hydrogen or alkyl of 1-3 carbon atoms;

each m is independently an integer from 0-6;

R₂ is




each R₆ is independently H or alkyl of 1-4 carbons;

each R₇ is independently H, OH, or alkyl of 1-4 carbons;

each R₈ is independently H, or alkyl of 1-4 carbons, and is absent when a triple bond is present;

R₅ is COOR₄; CH₂OH; CHO; tetrazole; NHSO₂R₁₄; hydroxymethylketone; CN; CON(R₇)₂; a monocyclic or bicyclic heterocyclic ring containing an acidic hydroxyl group; or COOR₁₅ where R₁₅ is



wherein each s is independently 0-3;

R₁₆ is

A) a monocyclic or bicyclic heterocyclic radical containing from 3 to 12 nuclear carbon atoms and 1 or 2 nuclear heteroatoms selected from

- 65 -

N and S with at least one being N, and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or
 B) the radical W-R₁₇ wherein W is O, S or NH and R₁₇ contains up to 21 carbon atoms and is (1) a hydrocarbon radical or (2) an acyl radical of an organic acyclic or monocyclic carboxylic acid containing not more than 1 heteroatom in the ring;

R₁₄ is OH, alkyl or alkoxy of 1 to 6 carbon atoms, phenyl or phenyl substituted by alkyl or alkoxy groups of 1 to 3 carbon atoms, halogen, hydroxy, haloalkyl, COOH, CN, formyl, acyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 4 carbon atoms;

r and q are each independently 0-20 provided that the total of r and q does not exceed 20;

p is 0 or 1;

R₃ is alkyl of 1 to 6 carbon atoms which may be straight chain or branched; or alkenyl of 3 to 6 carbon atoms which may be straight chain or branched as illustrated in formulas IV and V;

R₉ is alkyl of 1 to 6 carbon atoms which may be straight chain or branched; alkoxy of 1 to 6 carbon atoms which may be straight chain or branched; or (CH₂)_rR₅; and

R₁₀ is H; alkyl of 1 to 6 carbon atoms which may be straight chain or

branched; $\text{R}_4\overset{\text{O}}{\underset{\parallel}{\text{C}}}-$ or R₄OCH₂-.

10. A method according to claim 9 wherein the compound has an IC₅₀ equal to or less than 10 μM in the hPPARδ binding assay and an EC₅₀ equal to or less than 10 μM in the hPPARδ transactivation assay.


- 66 -

11. The method of Claim 10 wherein the compound has an IC₅₀ equal to or less than 100 nM in the hPPAR δ binding assay and an EC₅₀ equal to or less than 100 nM in the hPPAR δ transactivation assay.


12. The method of Claim 11 wherein the compound has an IC₅₀ equal to or less than 50 nM in the hPPAR δ binding assay and an EC₅₀ equal to or less than 50 nM in the hPPAR δ transactivation assay.

13. The method of Claim 12 wherein the compound has an IC₅₀ equal to or less than 10 nM in the hPPAR δ binding assay and an EC₅₀ equal to or less than 10 nM in the hPPAR δ transactivation assay.

14. A method for raising high density lipoprotein plasma levels in a patient in need of such treatment, comprising the administration of a pharmaceutically effective amount of a compound of formula XI or XII:



and




- 67 -

or a pharmaceutically acceptable salt or acid addition salt thereof, wherein:

each R is independently H, OH, alkyl of 1 to 6 carbon atoms which may be straight chain or branched; alkenyl of 2 to 6 carbon atoms which may be straight chain or branched; trifluoromethyl; alkoxy of 1 to 6 carbon atoms which may be straight chain or branched; SH; thioalkyl of 1 to 6 carbon atoms which may be straight chain or branched; phenyl; phenyl substituted by alkyl of 1 to 3 carbon atoms or by halogen; benzyl; phenethyl; halogen, amino; $N(R_4)_2$ wherein R_4 is H or alkyl of 1 to 6 carbon atoms which may be straight chain or branched; $COOR_4$; CH_2OR_4 ; formyl; CN; trifluoromethylthio; or nitro;

each R' is independently R_4 ; OR_4 ; $COOR_4$; $N(R_4)_2$; SR_4 ; CH_2OR_4 ; CHO; or together R' and R' are O; CH_2 ; or



Y' is sulfur, sulfoxide, sulfone; $\begin{array}{c} \text{O} \\ \parallel \\ \text{S}=\text{NR}_{11} \end{array}$;

R_{11} is H, alkyl of 1-4 carbon atoms which may be straight chain or branched; alkanoyl of 1-4 carbon atoms which may be straight chain or branched; phenylsulfonyl; tosyl; NR_{12} wherein R_{12} is H, alkyl of 1-4

carbon atoms which may be straight chain or branched; or $\begin{array}{c} \text{O} \\ \parallel \\ \text{N}-\text{C}-\text{R}_{13} \end{array}$ wherein R_{13} is alkyl of 1-4 carbon atoms which may be straight chain or branched, alkoxy of 1-4 carbon atoms which may be straight chain or branched; N-CN, CH_2 , or C=O;


- 68 -

Y is Y' and oxygen;

each R_1 is independently hydrogen or alkyl of 1-3 carbon atoms;

each m is independently an integer from 0-6;

R_2 is




each R_6 is independently H or alkyl of 1-4 carbons;

each R_7 is independently H, OH, or alkyl of 1-4 carbons;

each R_8 is independently H, or alkyl of 1-4 carbons, and is absent when a triple bond is present;

R_5 is $COOR_4$; CH_2OH ; CHO ; tetrazole; $NHSO_2R_{14}$; hydroxymethylketone; CN ; $CON(R_7)_2$; a monocyclic or bicyclic heterocyclic ring containing an acidic hydroxyl group; or $COOR_{15}$ where R_{15} is



wherein each s is independently 0-3;

R_{16} is

A) a monocyclic or bicyclic heterocyclic radical containing from 3 to 12 nuclear carbon atoms and 1 or 2 nuclear heteroatoms selected from

- 69 -

N and S with at least one being N, and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or
 B) the radical W-R₁₇ wherein W is O, S or NH and R₁₇ contains up to 21 carbon atoms and is (1) a hydrocarbon radical or (2) an acyl radical of an organic acyclic or monocyclic carboxylic acid containing not more than 1 heteroatom in the ring;

R₁₄ is OH, alkyl or alkoxy of 1 to 6 carbon atoms, phenyl or phenyl substituted by alkyl or alkoxy groups of 1 to 3 carbon atoms, halogen, hydroxy, haloalkyl, COOH, CN, formyl, acyl of 1 to 6 carbon atoms or perfluoroalkyl of 1 to 4 carbon atoms;

r and q are each independently 0-20 provided that the total of r and q does not exceed 20;

p is 0 or 1;

R₃ is alkyl of 1 to 6 carbon atoms which may be straight chain or branched; or alkenyl of 3 to 6 carbon atoms which may be straight chain or branched as illustrated in formulas IV and V;

R₉ is alkyl of 1 to 6 carbon atoms which may be straight chain or branched; alkoxy of 1 to 6 carbon atoms which may be straight chain or branched; or (CH₂)_rR₅; and

R₁₀ is H; alkyl of 1 to 6 carbon atoms which may be straight chain or

branched; $\begin{array}{c} \text{O} \\ \parallel \\ \text{R}_4\text{C}- \end{array}$ or R₄OCH₂-.

15. A method according to claim 14 wherein the compound has an IC₅₀ equal to or less than 10 μM in the hPPARδ binding assay and an EC₅₀ equal to or less than 10 μM in the hPPARδ transactivation assay.

- 70 -

16. The method of Claim 15 wherein the compound has an IC₅₀ equal to or less than 100 nM in the hPPAR δ binding assay and an EC₅₀ equal to or less than 100 nM in the hPPAR δ transactivation assay.

17. The method of Claim 16 wherein the compound has an IC₅₀ equal to or less than 50 nM in the hPPAR δ binding assay and an EC₅₀ equal to or less than 50 nM in the hPPAR δ transactivation assay.

18. The method of Claim 17 wherein the compound has an IC₅₀ equal to or less than 10 nM in the hPPAR δ binding assay and an EC₅₀ equal to or less than 10 nM in the hPPAR δ transactivation assay.

19. A method for halting, preventing or reducing the risk of developing atherosclerosis and related disease events which comprises administering to a patient in need thereof an effective amount of a compound of Claim 9 in combination with a sulfonylurea, fibrate, HMG-CoA reductase inhibitor, beta-sitosterol inhibitor, cholesterol acyltransferase inhibitor, biguanides, cholestyramine, angiotensin II antagonist, melinamide, nicotinic acid, fibrinogen receptor antagonists, aspirin, α -glucosidase inhibitors, insulin secretagogue or insulin.

20. A method according to claim 19 wherein the compound has an IC₅₀ equal to or less than 10 μ M in the hPPAR δ binding assay and an EC₅₀ equal to or less than 10 μ M in the hPPAR δ transactivation assay.

21. The method of Claim 20 wherein the compound has an IC₅₀ equal to or less than 100 nM in the hPPAR δ binding assay and an EC₅₀ equal to or less than 100 nM in the hPPAR δ transactivation assay.

- 71 -

22. The method of Claim 21 wherein the compound has an IC₅₀ equal to or less than 50 nM in the hPPAR δ binding assay and an EC₅₀ equal to or less than 50 nM in the hPPAR δ transactivation assay.

23. The method of Claim 22 wherein the compound has an IC₅₀ equal to or less than 10 nM in the hPPAR δ binding assay and an EC₅₀ equal to or less than 10 nM in the hPPAR δ transactivation assay.

24. A composition for the treatment of diabetes or for lowering triglyceride levels or for halting, preventing or reducing the risk of developing atherosclerosis and related disease events, or for raising high density lipoprotein plasma levels, which comprises an inert carrier and an effective amount of a compound of Claim 1.

25. A composition for the treatment of diabetes which comprises an inert carrier and an effective amount of a compound of Claim 1, in combination with a sulfonylurea, fibrate, HMG-CoA reductase inhibitor, beta-sitosterol inhibitor, cholesterol acyltransferase inhibitor, biguanides, cholestyramine, angiotensin II antagonist, melinamide, nicotinic acid, fibrinogen receptor antagonists, aspirin, α -glucosidase inhibitors, insulin secretagogue or insulin.

26. A composition for halting, preventing or reducing the risk of developing atherosclerosis and related disease events, or for raising high density lipoprotein plasma levels, which comprises an inert carrier and an effective amount of a compound of Claim 1, in combination with a sulfonylurea, fibrate, HMG-CoA reductase inhibitor, beta-sitosterol inhibitor, cholesterol acyltransferase inhibitor, biguanides, cholestyramine, angiotensin II antagonist, melinamide, nicotinic acid, fibrinogen receptor antagonists, aspirin, α -glucosidase inhibitors, insulin secretagogue or insulin.

27. A composition according to claim 26 wherein the compound has an IC₅₀ equal to or less than 10 μ M in the hPPAR δ

- 72 -

binding assay and an EC₅₀ equal to or less than 10 μ M in the hPPAR δ transactivation assay.

28. The composition of Claim 27 wherein the compound has an IC₅₀ equal to or less than 100 nM in the hPPAR δ binding assay and an EC₅₀ equal to or less than 100 nM in the hPPAR δ transactivation assay.

29. The composition of Claim 28 wherein the compound has an IC₅₀ equal to or less than 50 nM in the hPPAR δ binding assay and an EC₅₀ equal to or less than 50 nM in the hPPAR δ transactivation assay.

30. The composition of Claim 29 wherein the compound has an IC₅₀ equal to or less than 10 nM in the hPPAR δ binding assay and an EC₅₀ equal to or less than 10 nM in the hPPAR δ transactivation assay.

31. A composition for the treatment of obesity which comprises an inert carrier and an effective amount of a compound of Claim 1, in combination with a fenfluramine, dexfenfluramine, phentiramine or β ₃ adrenergic receptor agonist.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/01875

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :A61K 31/095, 31/10

US CL :514/706,708

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/706,708

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4,847,255 A (COLLINGTON et al.) 11 July 1989, column 1, lines 13-27.	1-31

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A		document defining the general state of the art which is not considered to be of particular relevance
* E		earlier document published on or after the international filing date
* L		document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
* O		document referring to an oral disclosure, use, exhibition or other means
* P		document published prior to the international filing date but later than the priority date claimed
	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
	* Z	document member of the same patent family

Date of the actual completion of the international search 09 MAY 1997	Date of mailing of the international search report 22 MAY 1997
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer Theodore J. Crites Telephone No. (703) 308-1235

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/01875

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS:

TERMS SEARCHED: DIABETES AND SULFONYL

OBESITY AND SULFONYL

ATHEROSCLEROSIS AND SULFONYL



United States Patent
Baker, et. al.

5,462,954
Oct. 31, 1995

Substituted phenyl phenol leukotriene antagonists

Inventors: **Baker; S. Richard** (Indianapolis, IN); **Dillard; Robert D.** (Zionsville, IN);
Floreancig; Paul E. (Mountain View, CA); **Sawyer; J. Scott** (Indianapolis, IN);
Sofia; Michael J. (Carmel, IN).

Assignee: **Eli Lilly and Company** (Indianapolis, IN).

Appl. No.: **333,122**

Filed: **Nov. 1, 1994**

Related U.S. Application Data

Continuation of (including streamline cont.) Ser. No. 797,522, Nov. 25, 1991, abandoned.

Intl. Cl. : **A61K 31/19, A61K 31/41, C07D 257/04, C07D 311/24, C07C 59/68, C07C 65/24**

Current U.S. Cl.: **514/381; 514/13; 514/14; 514/15; 514/16; 514/17; 514/18; 514/19; 514/232.8; 514/233.5; 514/237.8; 514/238.8; 514/239.2; 514/239.5; 514/252; 514/318; 514/332; 514/340; 514/343; 514/346; 514/347; 514/351; 514/520; 514/521; 514/570; 514/571; 548/250; 548/252; 562/463; 562/466; 562/469; 562/471**

Field of Search: **514/381, 13, 14, 15, 16, 17, 18, 19, 235, 252, 318, 332, 340, 343, 346, 347, 351, 520, 521, 570, 571; 548/250, 252; 562/463, 466, 471**

References Cited | [Referenced By]

U.S. Patent Documents

3,652,645	Mar., 1972	Leigh et al.	562/463
3,671,580	Jun., 1972	Shen et al.	562/469
3,755,603	Aug., 1973	Harrison et al.	562/469 X
3,882,148	May, 1975	Augstein et al.	260/345.2
<u>3,972,934</u>	Aug., 1976	Marshall	260/570.8
<u>4,136,192</u>	Jan., 1979	Buckle et al.	424/281
<u>4,153,807</u>	May, 1979	Adams et al.	562/469
<u>4,219,668</u>	Aug., 1980	Chiccarelli et al.	562/469
<u>4,252,817</u>	Feb., 1981	Closse et al.	562/469 X
<u>4,281,008</u>	Jul., 1981	Chamberlain et al.	424/269

<u>4,424,231</u>	Jan., 1984	Bantick et al.	424/274
<u>4,474,788</u>	Oct., 1984	Bantick	424/258
<u>4,499,299</u>	Feb., 1985	Bernstein et al.	514/570
<u>4,507,498</u>	Mar., 1985	Carson et al.	562/463
<u>4,565,882</u>	Jan., 1986	Miyano et al.	549/399
<u>4,567,184</u>	Jan., 1986	Musser et al.	514/227
<u>4,567,279</u>	Jan., 1986	Chan	548/491
<u>4,650,812</u>	Mar., 1987	Cohen et al.	514/456
<u>4,661,505</u>	Apr., 1987	Marshall et al.	514/381
<u>4,665,203</u>	May, 1987	Miyano et al.	549/402
<u>4,820,867</u>	Apr., 1989	Belanger et al.	562/478
<u>4,853,398</u>	Aug., 1989	Carr et al.	514/381
<u>4,874,777</u>	Oct., 1989	Carr et al.	514/381
<u>4,899,871</u>	Dec., 1989	Djuric et al.	514/456
<u>4,945,099</u>	Jul., 1990	Bollinger et al.	514/381
<u>4,952,705</u>	Aug., 1990	Miyano et al.	548/525
<u>4,992,576</u>	Feb., 1991	Capinski	560/52
<u>4,996,230</u>	Feb., 1991	Gapinski	514/454
<u>5,004,743</u>	Apr., 1991	Young et al.	514/227.8
<u>5,087,634</u>	Feb., 1992	Reitz et al.	548/252 X

Foreign Patent Documents

0003847	Sept., 1979	EP	562/469
028063	May, 1981	EP	514/381
056172	Jul., 1982	EP	514/381
132366	Jan., 1985	EP	514/381
0140684A	Aug., 1985	EP	562/463
355617	Feb., 1990	EP	514/381
405116	Jan., 1991	EP	514/381
0544488	Feb., 1993	EP	562/463
2173778	Oct., 1973	FR	514/456
57-35543	Feb., 1982	JP	562/469
1111361	Apr., 1968	GB	514/381
2329037	Dec., 1974	GB	562/469
1396726	Jun., 1975	GB	562/469

Other References

Therapeutic Patents Fast Alert, 2(17), AG20 (1991).

Buckle, et al., II, J. Med. Chem., 22(2), 158 (1979).

Chemical Abstracts 68:60277j (1968) (Mitsubishi).

LeMahieu, et al., J. Med. Chem., 30(1), 173 (1987).

Krell, et al., Advances in Prostaglandin, Thromboxane, and Leukotriene Research, 20, B. Sameulsson, et al., (Raven Press Ltd., New York 1990), p. 119.

Shaw, et al., J. Med. Chem., 34(4), 1235 (1991).

Konno, et al., II, Advances in Prostaglandin, Thromboxane, and Leukotriene Research, vol. 21, B. Sameulsson, et al., ed. (Raven Press, Ltd., New York 1990), p. 411.

Djuric et al., II, J. Med. Chem., 32(6), 1145 (1989).

"Leukotrienes and Lipoxygenase", J. Rokach, ed. (Elsevier, Amsterdam 1989), pp. 427-431 and 479-502 (Fitzsimmons et al.).

Siegel, et al., Monatsh., 88, 228 (1957).

Primary Examiner: Higel; Floyd D.

Attorney, Agent or Firm: Benjamin; Roger S., Conrad; Robert A.

Abstract

Antagonists having a substituted phenyl phenol or a substituted phenolic biphenyl structure, and various derivatives thereof, are specific leukotriene antagonists. Their structures, use and synthesis are disclosed. Also, pharmaceutical formulations are disclosed for use in applications treating diseases or conditions characterized by excessive release of leukotriene B(4), one of the metabolites of arachidonic acid.

The primary LTB(4) antagonistic structures are represented as: ##STR1##

38 Claims, No Drawings

[USPTO]



(1 of 3)

[USPTO]



(3 of 3)

United States Patent

4,820,867

Belanger, et. al.

Apr. 11, 1989

Phenoxypropoxy halophenylacetic acids as leukotriene antagonists

Inventors: **Belanger; Patrice** (Dollard des Ormeaux, CA); **Fortin; Rejean** (Montreal, CA); **Guindon; Yvan** (Quebec, CA); **Yoakim; Christiane** (Montreal, CA); **Rokach; Joshua** (Laval, CA).

Assignee: **Merck Frosst Canada, Inc.** (Quebec, CA).

Appl. No.: **855,051**

Filed: **Apr. 22, 1986**

Related U.S. Application Data

Continuation of (including streamline cont.) Ser. No. 591,344, Mar. 19, 1984, abandoned, which is a continuation-in-part of Ser. No. 487,434, Apr. 21, 1983, abandoned.

Intl. Cl. :

C07C 65/01

Current U.S. Cl.:

562/478; 548/134; 548/339.1; 564/99; 568/325

Field of Search:

562/478; 548/134, 313; 564/99; 568/325

References Cited | [Referenced By]

U.S. Patent Documents

3,899,513	Aug., 1975	Warren et al.	260/465.F X
-----------	------------	---------------	-------------

Foreign Patent Documents

0028063	May, 1981	EP
0056172	Jul., 1982	EP
0061800	Oct., 1982	EP
0104885	Apr., 1984	EP
0106565	Apr., 1984	EP
2058785	Apr., 1981	GB

Other References

Bailey et al., Ann. Rpts., Med. Chem., 17, 203 (1982).

Primary Examiner: Sutton; Anton H.

Attorney, Agent or Firm: Lopez; Gabriel, Pfeiffer; Hesna J.

Abstract

Compounds of the formula: ##STR1## are antagonists of leukotrienes of C(4), D(4) and E(4), the slow reacting substance of anaphylaxis. These compounds are useful as anti-asthmatic, anti-allergic and anti-inflammatory agents.

9 Claims, No Drawings

[USPTO]



(3 of 3)

[USPTO]



(2 of 2)

United States Patent

5,453,443

Perrier, et. al.

Sept. 26, 1995

Bis(aryloxy)alkanes as inhibitors of phospholipase A.sub.2 enzymes

Inventors: **Perrier; Helene** (Velle Ile Perrot, CA); **Prasit; Petpiboon** (Kirkland, CA); **Street; Ian** (St.-Lazare, CA); **Wang; Zhaoyin** (Pierrefonds, CA).

Assignee: **Merck Frosst Canada, Inc.** (Kirkland, CA).

Appl. No.: **277,854**

Filed: **Jul. 20, 1994**

Intl. Cl. :

A61K 31/19

Current U.S. Cl.:

514/570; 514/533; 514/534; 514/545; 514/571; 560/11; 560/15; 560/60; 562/429; 562/431; 562/459; 562/463; 562/470; 562/472

Field of Search:

562/429, 431, 459, 463, 470, 472; 560/11, 15, 60; 514/570, 571, 533, 532, 545

References Cited | [Referenced By]

U.S. Patent Documents

<u>4,820,867</u>	Apr., 1989	Belanger et al.	562/478
<u>5,135,940</u>	Aug., 1992	Belanger et al.	514/381

Foreign Patent Documents

0476849A2	Mar., 1992	EP
0501779A1	Sept., 1992	EP
0509719A1	Oct., 1992	EP

Primary Examiner: Dees; Jose G.

Assistant Examiner: Barts; Samuel

Attorney, Agent or Firm: Panzer; Curtis C., Rose; David L.

Abstract

Compounds having the formula I: ##STR1## are inhibitors of the PLA(2) s enzymes. These compounds are useful as anti-allergic, anti-asthmatic, they are also useful in treating various inflammatory diseases such as rheumatoid arthritis, osteoarthritis, bursitis, psoriasis; immunoinflammatory disorders such as contact dermatitis, irritable bowel disease and the like.

12 Claims, No Drawings

[USPTO]

